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Abstract 
 
Hyperuricaemia is a chronic condition associated with diseases of the 
metabolic syndrome. However, the cause and effect relationship between 
increased serum uric acid (UA) levels and the pathophysiology of metabolic 
dysfunction is far from clear. From an immunological angle hyperuricaemia 
has been shown to modulate inflammatory signalling in both immune and non-
immune cell types. Blood monocytes are constantly exposed to soluble UA in 
the circulation but the direct effect of this exposure has not been examined. 
This research focuses on the how soluble UA alters blood monocyte 
responses to inflammatory stimuli using in vitro, in vivo and clinical 
manipulation of UA levels. 
 
The Harper group previously found that blood monocytes from hyperuricaemic 
individuals produced lower levels of inflammatory cytokines compared to 
monocytes from healthy controls when stimulated ex vivo with LPS. My 
research began by studying the direct effect of soluble UA on human blood 
monocytes in vitro. I found that soluble UA reduced monocyte production of 
pro-inflammatory cytokines and increased IL-10 in response to stimulation 
with LPS. I identified two inflammatory signalling pathways modulated by 
soluble UA that could be contributing to this suppressive monocyte 
phenotype: MAP kinase phosphorylation was reduced alongside increased 
expression of the regulatory protein DUSP10 and reduced ASC; there was a 
switch towards anti-inflammatory NFκB signalling illustrated by decreased p65 
and increased p50 nuclear translocation. 
 
To study the modulation of soluble UA levels in a physiological context I 
raised serum UA levels in vivo with a model of acute hyperuricaemia and 
lowered serum UA using two clinically relevant medications: allopurinol and 
rasburicase. Consistent with in vitro UA treatment, raising serum UA levels in 
vivo suppressed pro-inflammatory cytokine responses to LPS, increased IL-10 
and down-regulated monocyte MAP kinase and NFκB signalling pathways. 
Abstract 
 
iv 
Acute urate-lowering therapy (ULT) with allopurinol or rasburicase reversed 
this suppressive inflammatory cytokine and signalling pattern. 
The PLT2 mouse strain has had the purine metabolic pathway disrupted by 
random mutagenesis of the gene encoding 5-hiydroxyisourate hydrolase, the 
enzyme responsible for degradation of the molecule directly downstream of 
UA, 5-hydroxyisourate. I found that this mutation resulted in chronic 
hyperuricaemia with an average 2-fold increase in serum UA over C57 mice. 
LPS challenge resulted in increased IL-10 production in PLT2 mice compared 
to C57, however no differences in monocyte inflammatory signalling were 
observed between the two strains. Acute ULT with rasburicase reduced 
serum UA in the PLT2 strain and subsequent LPS challenge increased 
monocyte inflammatory signalling.  
 
Finally, I studied the effects of ULT on the inflammatory phenotype of human 
blood monocytes from patients with hyperuricaemia. ULT significantly reduced 
serum UA levels, which coincided with reduced blood monocyte percentages 
and adhesion molecule expression (CD11b and ICAM1). ULT increased the 
inflammatory potential of human blood monocytes: Monocytes stimulated with 
LPS produced less IL-10; MAP kinase phosphorylation increased alongside 
increased ASC expression; nuclear translocation of NFκB p65 was increased. 
ULT also increased expression of the NLRP3 inflammasome components pro-
caspase1, pro-IL-1β and NLRP3. 
 
Taken together these results demonstrate a previously unidentified role for 
soluble UA in moderating monocyte immune responses to inflammatory 
stimuli. In vitro, in vivo and clinical experimentation all confirmed the 
immunosuppressive function of soluble UA. This potentially places UA in the 
centre of innate immune control through the dichotomy of its suppressive 
soluble effects, demonstrated herein, and the widely reported inflammatory 
crystalline effects. Importantly, this research illustrates that serum UA levels 
can be manipulated in a clinical setting to control the inflammatory phenotype 
of circulating immune cells. 
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1 General introduction 
Elevated serum uric acid (UA) was first identified in patients with gout by 
Alfred Baring Garrod in 18481. We have now come to recognise that soluble 
uric acid (UA) plays a multifaceted role in a multitude of inflammatory 
diseases including metabolic syndrome and neurological disorders. However, 
it is still unclear whether hyperuricaemia (>0.42mM serum UA) is protective or 
contributes to metabolic disorders such as heart disease, obesity and type 2 
diabetes2. Furthermore, there is a paucity of information regarding the direct 
effect of soluble UA on immune cell function during inflammation and disease. 
Identifying how soluble UA interacts with immune cells could provide 
important insights into the pathophysiology of hyperuricaemia in the context of 
metabolic disorders and the role soluble UA plays in homeostasis of the 
immune system. 
 
1.1 Purine metabolism 
The purine metabolic pathway describes the generation and breakdown of 
nucleotides for DNA synthesis, namely adenosine and guanosine. Uric acid 
(UA) is the end product of purine degradation in humans, whereas in most 
mammals allantoin is the end product (figure 1.1). Adenosine and guanosine 
are broken down through a series of enzymatic steps into hypoxanthine and 
xanthine respectively3. From this point a single enzyme, xanthine 
oxidoreductase (XOR), catalyses the production of UA. In most mammals UA 
is then oxidised by uricase into 5-hydroxyisourate (HIU) and two more 
enzymatic steps catabolise HIU into the end product allantoin, which is then 
excreted via the kidneys and urine4.  
 
1.2 Evolutionary mutational silencing of uricase 
During our common evolution, humans and higher primates acquired a series 
of mutations in the uricase gene that has resulted in a complete loss of 
function5. These mutations have been traced back to different periods of 
species divergence in the hominids and great apes. 
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Figure 1.1 Purine metabolic pathway.  
Humans no longer have a functional uricase enzyme. This makes uric acid the 
endpoint of purine degradation in humans. ATP: Adenosine triphosphate, GTP: 
Guanosine triphosphate, XOR: Xanthine oxidoreductase, HIU: 5-hydroxyisourate, 
OHCU: 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline. 
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Combined with the evolutionary loss of uricase is the efficient retention of UA 
in humans by reabsorption via UA transporters in the kidneys, such that about 
90% of the UA that is filtered through the kidneys is reabsorbed into the 
blood6. This contributes to average serum UA levels in humans of around 
0.36mM (6mg/dl), 10-fold higher than most other mammals.  
There are several theories regarding the drivers of evolutionary selection for a 
loss of uricase function and increased serum UA.  
Firstly, increased serum UA may have played a key role during human 
evolution by maintaining the higher blood pressure required to support bipedal 
motility and upright posture during periods of low salt availability7. This is 
supported by data showing a strong association between hyperuricaemia and 
hypertension8.  
Secondly, soluble UA has anti-oxidant properties that could be important for 
reducing the damage and the risk of developing diseases associated with 
increased oxidative stress. UA is reported to be as effective as ascorbate in 
reducing oxidative damage in erythrocytes9. This study also suggests that as 
UA is present at much higher concentrations than ascorbate in serum it may 
account for up to 60% of the anti-oxidant capacity in the serum.  
In this way increased serum UA during evolution may have promoted 
neuroprotection, as the brain is very sensitive to damage induced by oxidative 
stress. This is supported by recent meta-analyses that further confirm the 
association between increased serum UA levels and reduced risk and 
progression of neurological disorders such as Parkinson’s disease10 and 
Alzheimer’s11.  
The anti-oxidant properties of UA may also protect humans from multiple 
sclerosis (MS) by reducing the damage caused by reactive oxygen and 
nitrogen species12. This is corroborated by studies showing lower levels of UA 
in the serum and cerebrospinal fluid in patients with MS compared to age and 
sex matched controls13,14 and lower UA levels in MS patients with active 
disease than patients in remission15. Despite these clear associations there 
has been limited success in clinical trials aiming to treat MS by raising serum 
UA levels16,17.  
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Thirdly, soluble UA can also have pro-oxidant effects as evidenced by the 
oxidation of UA by peroxynitrite, which can produce an aminocarbonyl 
radical18, and the reaction of UA with myeloperoxidase that can produce a 
urate radical19. In this way, increased soluble UA may support ROS 
dependent intracellular signalling as both the NFκB and MAP kinase 
signalling pathways are redox sensitive20,21. Furthermore, the generation of 
extracellular ROS by UA oxidation could aid in the killing of pathogens during 
inflammation. This does not necessarily contradict the anti-oxidant theory 
described above but indicates that perhaps both the pro- and anti-oxidant 
effects of increased soluble UA support the evolutionary loss of uricase.  
Together these theories and the supporting studies indicate that the loss of 
uricase and increase in serum UA in early man could have provided a 
selective advantage and was not just a random occurrence. 
 
1.3 Dysregulation of UA homeostasis 
1.3.1 Hypouricaemia (serum UA <0.12mM or <2mg/dl) 
Hypouricaemia is rare in humans and can be caused by a heritable loss of 
function mutation in the urate transporters URAT1 or Glut9 that results in 
reduced renal reabsorption and excessive urinary excretion of soluble UA22-24. 
Alternatively, a loss in function mutation in XOR reduces uric acid production 
and is the cause of hereditary xanthinuria6. The physiological effects of 
hypouricaemia include urolithiasis and exercise induced acute renal failure25-
28. This indicates that serum UA may have an important role in maintaining 
proper kidney function. 
 
1.3.2 Risk factors for hyperuricaemia (serum UA >0.42mM or >7mg/dl)  
Age 
Serum UA levels increase with age. This is evident from the increased 
prevalence of hyperuricaemia and gout in the ageing population and may be a 
result of decreased kidney function and renal UA excretion or a combination 
of risk factors for hyperuricaemia that all increase with age29,30.  
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Gender 
Men in general have higher serum UA levels than women and are therefore 
more prone to developing hyperuricaemia but this gender discrepancy 
decreases after women reach menopause31. The UA lowering effect of 
estrogens have been clearly demonstrated by an inverse relationship between 
estrogens and serum UA during the menstrual cycle and the association 
between postmenopausal hormone use and lower serum UA levels32,33. 
Additionally, it has been demonstrated that testosterone treatment can 
increase serum UA levels34 further explaining the clear gender difference 
present in serum UA levels.  
 
Medication 
A common side effect of many medications is decreased renal function. Most 
medications require clearance via the kidneys and urinary excretion. As such, 
medication can have either a general negative effect on renal function or a 
more specific negative effect on UA excretion. For example, low dose aspirin 
and diuretics can decrease renal UA excretion by competing for UA with 
organic ion transporters in the kidney35.  
 
Genetics 
UA excretion involves several stages of renal tubular filtration, secretion and 
reabsorption6. URAT1, Glut9, ABCG2 and several other organic anion 
transporters are responsible for this process and heritable polymorphisms 
within the genes for these transporters have been identified as major 
contributors to the risk of developing hyperuricaemia22,36,37. This has been 
further demonstrated in population-based studies linking the prevalence of 
different genetic polymorphisms to the incidence of gout 38-40. The rs2231142 
polymorphism is a glutamine to lysine mutation at amino acid 141 (Q141K) in 
the ABCG2 transporter that produces a loss of transporter function which 
decreases extra-renal UA secretion37,41. 
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Diet 
A purine rich diet, especially one high in seafood, can increase serum UA 
levels as a result of increased purine metabolism and production of UA42. It 
has been shown that increased alcohol consumption, especially beer, 
increases the incidence of hyperuricaemia43,44. This can be attributed to the 
high purine content of beer and the convergence of the purine and ethanol 
metabolic pathways. Ethanol metabolism increases degradation of ATP, 
which enhances purine metabolism and results in increased UA production45. 
Ethanol metabolism also increases lactate production, which is a competitive 
inhibitor of UA excretion46,47. Excess fructose consumption, especially from 
sugar-sweetened beverages, has also been shown to contribute to 
hyperuricaemia48,49. The mechanism is similar to ethanol, in that fructose 
metabolism increases purine nucleotide metabolism and lactate production50 
and may also involve a direct effect of increased glucose and fructose on 
urate transport, as these sugars are also substrates for the Glut9 transporter51.   
 
Lifestyle 
Healthy eating and exercise habits are also important factors in maintaining 
normal serum UA levels. This has been demonstrated with interventional trials 
where treatment of patients with gout or obesity consisted of caloric 
restriction52 or a low calorie diet and exercise53. It was found that these 
treatments lowered serum UA levels and improved renal UA excretion 
indicating that a poor diet and sedentary lifestyle can contribute to 
hyperuricaemia.  
 
Ultimately, these risk factors combine together to increase production and/or 
decrease excretion of soluble UA, increasing the risk of developing 
hyperuricaemia. 
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1.4 Diseases associated with UA dysregulation 
While humans may have evolved to have higher UA levels compared to other 
mammals this has predisposed humans to developing hyperuricaemia when 
control of UA homeostasis is perturbed. Hyperuricaemia is associated with a 
plethora of diseases but the role of soluble UA in exacerbating the 
pathophysiology of these diseases is still not fully understood. 
 
1.4.1 Kidney disease 
Hyperuricaemia is recognised as a risk factor for the development of acute 
kidney injury. This is clearly demonstrated during tumour lysis syndrome 
where massive tumour cell death occurs as a result of chemotherapy for 
haematological malignancy54. The breakdown and release of tumour cell 
contents into the blood stream causes serum UA levels to spike and can 
result in severe renal nephropathy55. However, in chronic kidney disease it is 
difficult to separate the independent effects of raising serum UA levels from 
other pathologies associated with hyperuricaemia and kidney disease. As 
such, definitive causation has not yet been shown in humans6. 
 
1.4.2 Hypertension and cardiovascular disease 
Hypertension is closely associated with hyperuricaemia but whether the high 
serum UA levels cause hypertension is still the subject of debate. Urate-
lowering therapy (ULT) has been shown to reduce essential hypertension56. 
However, the association between hypertension and hyperuricaemia weakens 
with increasing patient age and duration of hypertension57. Additionally, there 
has been a lack in consistency between genome wide association studies 
investigating the effects of polymorphisms in UA transporters on hypertension 
and Johnson et al. posit that this could stem from a difference in function 
between intracellular and serum UA58. In this case, hyperuricaemia without 
hypertension could result from more active urate transporters reducing 
intracellular UA levels to decrease endothelial dysfunction and vascular 
stiffening but the increased urate transporter function would also increase 
serum UA levels. 
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Hyperuricaemia is only weakly associated with heart disease and this link can 
potentially be explained by the association of hyperuricaemia with 
hypertension, a true risk factor for heart disease. However, hyperuricaemia 
has been shown to induce endothelial dysfunction by reducing eNOS activity 
in endothelial cells59-61 and endothelial dysfunction, a predictor of 
cardiovascular disease, precedes atherosclerotic plaque formation3,62. 
Therefore, it could be argued that hyperuricaemia is indeed a risk factor for 
cardiovascular disease progression through its contribution to endothelial 
dysfunction. This link is supported by a study where hyperuricaemia was an 
independent predictor of mortality in patients with type 2 diabetes and 
coronary artery disease63. 
 
1.4.3 Type 2 diabetes and obesity 
These diseases share common characteristics such as dyslipidaemia, insulin 
resistance and low-grade chronic inflammation. However, the contribution of 
hyperuricaemia to the pathogenesis of these disorders is still unclear.  
 
Hyperuricaemia is associated with an increased risk of developing type 2 
diabetes and there is an argument for hyperuricaemia, as a result of 
excessive fructose intake, being a significant contributor to the current 
metabolic syndrome and diabetes epidemic64,65. Like cardiovascular disease, 
the contribution of hyperuricaemia to type 2 diabetes may be through its 
contribution to endothelial dysfunction and low-grade chronic inflammation, as 
demonstrated in a recent study connecting new onset diabetes in 
hypertensive patients to hyperuricaemia66. Another study showed a direct 
effect of soluble UA in producing intracellular oxidative damage that inhibited 
the growth of pancreatic β-cells in vitro67. However, an earlier study found that 
hyperuricaemia increased the risk of developing hypertension but not diabetes, 
indicating hyperuricaemia may not be a suitable prognostic marker for 
diabetes in every situation68.  
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Obesity can be classified into either metabolically healthy or unhealthy, which 
pertains to a decreased or increased risk of developing cardiovascular 
disease respectively69. Interestingly, one of the main predictors of unhealthy 
obesity is hyperuricaemia but obesity itself can contribute to hyperuricaemia 
by increasing purine metabolism within adipose tissue70. This highlights the 
difficulty of differentiating between the contribution of hyperuricaemia to the 
disease and the contribution of the disease to hyperuricaemia.  
Experimentally, soluble UA activates MAP kinase signalling in adipocytes 
through increased ROS production and oxidative stress71. Another study 
showed that adipocytes treated with soluble UA decreased production of the 
anti-inflammatory adipokine adiponectin and increased production of CCL2, a 
major monocyte chemokine, and that lowering serum UA in obese mice 
reduced insulin resistance and adipose tissue macrophages72. These results 
indicate that hyperuricaemia directly contributes to metabolic syndrome 
related pathology by increasing oxidative stress. 
 
Together these studies indicate that elevated serum UA is an indicator of 
general metabolic dysfunction that may also contribute to the pathology of 
metabolic syndrome related disorders. However, recent epidemiological 
studies using Mendelian randomisation, which uses traits linked to genetic 
polymorphisms of known susceptibility to control for observational bias and 
confounding co-morbidities, suggest that there is no causal effect of 
hyperuricaemia in metabolic syndrome related disorders and may be 
confounded by a causal effect of increased body mass index on serum UA 
levels and risk of developing hyperuricaemia73-75. 
 
1.4.4 Gout 
The one metabolic disorder that has been definitively linked to hyperuricaemia 
is gout. Gout is caused by the formation of monosodium urate (MSU) crystals 
in joints and periarticular spaces76. These crystals trigger a severe, self-
limiting auto-inflammatory response77. At physiological temperature in 
biological fluids UA has an upper solubility limit of 0.42mM (7mg/dl) and 
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above this level the risk of an acute gouty attack increases as the 
hyperuricaemia worsens78. 
As the crystallisation event is key to the pathophysiology of gout it is clear that 
hyperuricaemia is only a risk factor for gout while crystallisation of UA and the 
ensuing auto-inflammation is the cause. This is an important distinction, as it 
defines the immunological action of crystalline UA as functionally different 
from soluble UA (discussed further in section1.8). 
 
1.5 Treatment of hyperuricaemia 
Currently, treatment for hyperuricaemia is limited to two main indications. The 
first, and most common, is gout.  The second is tumour lysis syndrome. 
There are three mechanisms through which UA levels can be 
pharmacologically manipulated (figure 1.2) and by combining these with diet 
and lifestyle changes hyperuricaemia can be effectively treated and controlled 
in the majority of individuals. 
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Figure 1.2 Different mechanisms of pharmacological urate-lowering therapy.  
XOR inhibitors prevent formation of UA, recombinant uricase therapy metabolises 
excess UA and uricosurics increase renal UA excretion. XOR = xanthine 
oxidoreductase. 
 
1.5.2 Xanthine oxidoreductase (XOR) inhibition 
XOR is the enzyme that produces UA from hypoxanthine and xanthine (figure 
1.2) making XOR a logical target for pharmacological inhibition. However, the 
efficacy of XOR inhibition hinges on efficient renal UA clearance. For example, 
people with genetic variants in urate transporters may not respond well to 
XOR inhibition because efficient renal UA reabsorption reduces the clearance 
rate of excess UA.  
From an immunological standpoint XOR is recognised as a significant source 
of reactive oxygen species (ROS), which are involved in inflammatory 
signalling and vascular oxidative stress79,80. Therefore, XOR inhibition will 
reduce both UA and ROS. Being able to differentiate between the effects of 
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lowering serum UA and decreasing ROS is an important consideration when 
assessing the immunological outcomes of UA reduction with a XOR inhibitor. 
 
Allopurinol 
Allopurinol has been the mainstay of urate-lowering therapy (ULT) for the past 
40 years as it is generally well tolerated and has few serious side effects81. In 
certain cases treatment with allopurinol can result in the precipitation of an 
acute gout attack, the aetiology of which is still unknown. Less likely, but more 
severe, is development of allopurinol hypersensitivity syndrome (AHS). The 
presence of the HLA-B*5801 allele has been linked with an increased risk of 
developing AHS but the exact mechanism is unknown82. These side effects 
have resulted in the development of cautious dosing regimes that start at 50 
or 100mg/day and escalate slowly until target serum UA is achieved at which 
point the allopurinol dose is maintained83. 
 
Febuxostat 
Febuxostat is the only other XOR inhibitor to come onto the market and has 
only done so in the last few years. Comparisons with allopurinol have shown 
febuxostat to be more selective in its inhibition of XOR84 and to provide better 
UA lowering with a lower dose85-87. Febuxostat has a small human side effect 
profile, however there have been reports of neutropenia or cardiovascular 
thromboembolic events as a result of febuxostat treatment88,89. 
 
1.5.3 Recombinant uricase 
The development of recombinant uricase for the treatment of hyperuricaemia 
is relatively recent. Uricase breaks down UA into HIU (figure 1.1), which in the 
absence of HIU-hydrolase and OHCU-decarboxylase in humans can 
spontaneously degrade into allantoin but at a much slower rate than when 
enzymatically degraded4. Currently, the immunological and physiological 
functions of HIU and OHCU production during treatment of hyperuricaemia 
with recombinant uricase are unknown but need to be investigated to 
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determine the safety and suitability of recombinant uricase treatment. 
Recently, a mouse strain has been developed that has a loss of function 
mutation in the Urah gene that codes for HIU hydrolase and has been 
designated UrahPlt2/Plt2 (PLT2)90. The PLT2 strain has some growth 
abnormalities including hepatomegaly, increased platelet counts and 
development of spontaneous liver cancer after two years. However the role of 
increased HIU in these pathologies was not investigated. 
There are two recombinant uricase formulations currently approved for use in 
treating hyperuricaemia. Rasburicase is derived from Aspergillus flavus and 
pegloticase is of porcine origin and has been conjugated to polyethylene 
glycol91. Both rasburicase and pegloticase have been successful in the 
treatment of tumour lysis syndrome and can be prescribed for use in 
treatment-failure gout, where the patient has had an adverse reaction to 
allopurinol or allopurinol treatment has been ineffective92. However, there are 
safety concerns over the antigenicity of recombinant uricases that currently 
preclude them for long-term repeated use until studies on the effects of long-
term treatment are complete93. 
 
1.5.4 Uricosurics 
The third method of ULT is through uricosuria. This works by increasing renal 
clearance of UA and are recommended for treating hyperuricaemia in cases 
of renal UA underexcretion94. Three uricosurics are used clinically: 
benzbromarone, probenecid and losartan. These inhibit the URAT1 
transporter to prevent UA reabsorption in the proximal kidney tubule22,95. 
Benzbromarone was initially well received but has since been withdrawn from 
many countries due to the increased risk of hepatotoxicity94,96. Probenecid is 
the most widely used uricosuric and can be used as a monotherapy for 
allopurinol refractory gout and also in combination with allopurinol97. Losartan 
is prescribed primarily for treatment of hypertension but has off label 
uricosuric effects that make it a promising candidate for combined treatment 
of hypertension and hyperuricaemia, two conditions with a high rate of 
comorbidity98,99. Interestingly, a recent meta-analysis found that vitamin C 
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supplementation reduced serum UA levels in randomised controlled trials and 
implicates competitive inhibition of UA reabsorption through renal transporters 
as a possible mechanism100. Given the reported safety of high dose vitamin 
C101 this may provide an avenue for use in combination therapy of 
hyperuricaemia. 
 
1.5.5 Diet and lifestyle 
The association between excessive food consumption and gout is best 
exemplified by the moniker “disease of kings” which is how gout was 
perceived right up until the 20th century and long before hyperuricaemia was 
recognised as the primary risk factor102. However, there has been a rapid 
increase in the late 20th century in the prevalence of hyperuricaemia and 
associated metabolic diseases that coincides with the increased availability of 
calorie rich foods and increased sedentary lifestyle in western and 
westernising countries103,104. Education on how diet and lifestyle changes can 
be used to help ameliorate hyperuricaemia is common practice when initiating 
ULT for gout. Simple measures such as lowering consumption of alcoholic 
and fructose sweetened beverages or getting regular exercise can have a 
significant effect on the reduction of gout flares and metabolic comorbidities 
associated with hyperuricaemia83,105. However, diet and lifestyle modifications 
alone can sometimes be insufficient to significantly reduce serum UA levels 
and are more effective when combined with the right pharmacotherapy106. 
 
1.6 Immunological effects of UA 
1.6.1 Crystalline monosodium urate (MSU) 
The crystalline form of uric acid, MSU, is more than just the etiological agent 
in gout. UA was first identified as a powerful endogenous immune adjuvant in 
an elegant study by Shi et al. showing that UA was released from dying cells 
and was able to enhance adaptive immune responses by licensing DC in the 
presence of antigen107 (figure 1.3). They also demonstrated that by increasing 
and decreasing UA in vivo they could potentiate or restrict the generation of 
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CD8 T-cell responses respectively. These results led them to hypothesise that 
MSU was responsible for this adjuvanticity. To complement this research, the 
adjuvanticity of MSU has been recently demonstrated in a model of cancer 
immunotherapy whereby co-injection of MSU and M. smegmatis slowed 
tumour progression through the rapid induction of monocyte-derived DC108. 
The mechanism through which MSU activates immune cells is not fully 
understood. Knockout of CD14 on monocyte/macrophages reduces the 
inflammatory response to MSU109. Antibody blocking experiments have shown 
that the Fcγ receptor CD16 and adhesion molecule CD11b mediate activation 
of neutrophils to MSU110. These studies do not definitively show that receptor 
ligation of MSU by these molecules triggers the down stream inflammatory 
effects. However, they do indicate that the involvement of these receptors 
enhances inflammatory signalling in the case of CD14 or phagocytosis of 
MSU crystals in the case of CD16 and CD11b. This is supported by research 
showing that lipid sorting occurs upon contact of MSU crystals with the 
cellular membrane and activates the Syk kinase dependent signalling 
pathway which can initiate phagocytosis and inflammatory cytokine 
production111,112.   
The NLRP3 inflammasome is a multi-protein complex involved in the cleavage 
of pro-IL-1β and pro-IL-18 into their active forms113. The key components are 
NLRP3, the adaptor protein ASC and pro-caspase1. Activation of the NLRP3 
inflammasome brings these components together to trigger pro-caspase1 by 
autocatalytic cleavage. Active caspase1 can then cleave pro-IL-1β into active 
IL-1β for secretion.  
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Figure 1.3 Adjuvanticity of MSU. 
UA released from dying cells can form MSU crystals to activate the innate immune 
system (neutrophils and monocytes) and promote differentiation of monocytes into 
inflammatory DC, in the presence of antigen, to activate an adaptive immune 
response. 
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Endogenous danger signals such as ATP, CPPD and MSU can activate the 
NLRP3 inflammasome. However, it wasn’t until the recognition of MSU as an 
endogenous danger signal that Martinon and colleagues investigated the role 
MSU played in IL-1β maturation. It was discovered that MSU is a potent 
activator of the NLRP3 inflammasome and IL-1β maturation114. This discovery 
has led to a renewed interest in inflammasomes and the identification of many 
different inflammasomes in both mice and humans115. However, the NLRP3 
inflammasome is by far the best characterised.  
 
1.6.2 Soluble UA 
The role of soluble UA in inflammation and immunity has not been as 
extensively investigated. In contrast to MSU there are reports that soluble UA 
has an anti-inflammatory effect on inflammation. UA administration has been 
shown to reduce the severity of dsRNA-induced arthritis in mice, possibly 
through a decrease in granulocyte inflammatory activity116. Additionally, UV-
induced skin damage was shown to increase local soluble UA levels and 
immune suppression in vivo that could be both be inhibited with allopurinol 
treatment117. However, an inflammatory role for soluble UA has been 
proposed in obesity and metabolic syndrome whereby increased soluble UA 
levels increased inflammatory signalling in adipocytes and contributed to 
insulin resistance71,72. These effects were mediated by the pro-oxidant 
capabilities of soluble UA and demonstrate that soluble UA may have different 
functions depending on the specific cell type.  
 
1.7 Monocytes and metabolic disease 
Monocytes play multiple roles in innate immunity and in the crosstalk between 
innate and adaptive immunity. They are both effector and precursor cells that 
can alter their function as they adapt to the local environment and 
immunological stimuli. Monocytes produced in the bone marrow are recruited 
into the circulation by the chemokine-chemokine receptor axis CCL2-CCR2118. 
In the circulation monocytes make up approximately 5% of all immune cells 
and can be split into two contiguous sub-populations. The CD14+/CD16- 
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subset (Ly6C+ in mice) are circulating monocytes that are recruited to sites of 
inflammation, whereas CD14+/CD16+ monocytes (Ly6C- in mice) patrol in 
and out of the tissues and may be the population that replenishes the tissue 
resident macrophage pool119,120.  There is also a large population of 
monocytes resident in the spleen that can be recruited into the circulation and 
then to the tissues during an inflammatory event121.  
In the tissues monocytes initially respond to inflammatory stimuli by secreting 
cytokines and chemokines that activate and educate the immune system to 
combat the insult and begin the resolution process. They also begin 
differentiating into macrophages or dendritic cells (DC) depending on the 
nature of the inflammation. Macrophage differentiation occurs in sterile 
inflammation such as gout122. Monocyte-derived DC can be produced in 
response to adjuvant therapy and delay the growth of established tumours108. 
As they differentiate monocytes gain phagocytic capacity and the phenotypic 
and functional characteristics that the local environment requires for an 
effective innate or adaptive immune response to the specific insult.  
 
Despite their essential role during pathogen-induced inflammation, or perhaps 
because of it, monocytes are also key immune cells involved in the 
pathogenesis of metabolic disease.  
 
1.7.1 Kidney disease 
Cisplaten-induced acute renal failure is used as a model of tumour lysis 
syndrome-mediated renal injury and induces monocyte recruitment into the 
kidney. In this model hyperuricaemia exacerbated renal tubular injury 
compared to rasburicase treated rats, indicating a role for increased serum 
UA in exacerbating renal inflammation through increased monocyte 
recruitment123. Additionally, increased renal vasculopathy and macrophage 
infiltration was observed in hyperuricaemic mice after remnant kidney 
surgery124. However, blood monocytes isolated from patients with end stage 
renal disease were less inflammatory when stimulated ex vivo with LPS or 
MSU, indicating that the monocytes that invade as a result of renal 
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nephropathy are immunosuppressed and as such may be mitigating further 
disease125. 
 
1.7.2 Hypertension and cardiovascular disease 
Hypertension is associated with the recruitment of monocyte/macrophages 
into renal tissue. Here the macrophages can contribute to renal dysfunction 
and the development of hypertension through a combination of increased 
oxidative stress and angiotensin II activity126. 
During the formation of atherosclerotic plaques monocytes are recruited to the 
inflamed arterial wall and invade. Once inside the plaque, monocytes 
differentiate into macrophages and phagocytose the cholesterol crystals in an 
attempt to repair the damaged artery wall. Excessive cholesterol uptake can 
create a chronic cycle of macrophage foam cell formation, cell death and 
more monocyte recruitment127. In addition to this, hyperuricaemia is 
associated with increased monocyte recruitment into the circulation and 
soluble UA can stimulate CCL2 production, a major monocyte chemokine, in 
vascular smooth muscle cells128,129. This could potentially increase monocyte 
recruitment to atherosclerotic plaques in hyperuricaemic individuals. 
  
1.7.3 Type 2 diabetes and obesity 
Adipokines are the signalling molecules that control energy usage and fat 
deposition and monocytes express adipokine receptors, such as the leptin 
receptor, allowing them to respond to changes in metabolic signalling130. Their 
role as instigators or moderators of inflammation is still unknown, however 
monocytes respond to leptin by increasing their phagocytic capacity and 
cytokine production131. Furthermore, in patients with type 2 diabetes 
monocytes display an enhanced inflammatory phenotype and are more 
reactive when stimulated ex vivo 132,133 and adipose tissue macrophages are 
recognised as a driver of obesity related inflammation and insulin 
resistance134. This indicates that monocyte recruitment into adipose tissue 
could be an important factor in determining the severity and progression of 
disease and there may be an opportunity to target monocyte recruitment in 
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the treatment of metabolic syndrome. However, whether hyperuricaemia has 
a direct impact on monocyte recruitment to adipose tissue during type 2 
diabetes and obesity is unclear. 
 
1.7.4 Gout 
The role of monocytes and macrophages in gout has been well studied. 
Monocytes are recruited in large numbers into the inflamed synovium 
following initiation of an acute gouty attack77. Interestingly, resident 
macrophages are not required for this monocyte recruitment as the synovial 
epithelial cells are the main source of monocyte chemoattractants135. The 
monocytes that are recruited into an inflamed joint during gout are initially 
refractory to further MSU stimulation but gradually differentiate into hyper 
responsive resident macrophages that when stimulated produce an even 
more severe auto-inflammatory gouty attack136.  
 
1.8 Experimental hyperuricaemia 
In an effort to better understand the physiological and immunological effects 
of hyperuricaemia there have been many animal models developed.  
The majority of studies have used rodents as model animals, employing 
pharmacological, genetic and dietary manipulation of purine metabolism. 
Other organisms have also been investigated, such as silkworms for their use 
in testing new ULT137 and Dalmatians, as they have a unique heritable 
decrease in UA reabsorption that may be the result of endocrine signalling 
from the liver138.  
 
1.8.1 Pharmacological manipulation 
The most common pharmacological method of inducing hyperuricaemia is 
through the inhibition of uricase with oxonic acid, which is often delivered by 
intraperitoneal (i.p.) injection or orally and can be used to induce both acute 
and chronic hyperuricaemia. Many studies using oxonic acid are designed to 
test the efficacy of new compounds or extracts to lower serum UA levels139-141 
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but oxonic acid is also used for research into the effects of hyperuricaemia on 
metabolic dysfunction142,143.  
Inosine, a purine precursor that is broken down into UA has been used to 
raise serum UA levels in mice and was successful in treating experimental 
autoimmune encephalomyelitis144. 
 
1.8.2 Genetic manipulation 
Genetic ablation of the uricase enzyme has been used to create a mouse 
model of hyperuricaemia145. However, this mouse strain develops severe 
hyperuricaemia and nephropathy, as a result of MSU crystal deposition in the 
kidneys, followed quickly by death. Therefore, its use as an experimental 
mouse strain is limited, as it requires constant ULT for long-term survival. 
A hyperuricaemic mouse deficient in the UA transporter Glut9 has been 
developed146. Glut9 is important for UA transport into the liver, the main 
location of uricase, so this knockout develops hyperuricaemia as a result of 
impaired UA metabolism rather than underexcretion.  
Indirectly, models of hyperuricaemia have been created during development 
of genetically obese mice. This is exemplified by the leptin deficient (ob/ob) 
and leptin receptor deficient (db/db and Pound) mouse strains, which all 
develop hyperuricaemia alongside obesity and symptoms of metabolic 
dysfunction. The effect of lowering serum UA with allopurinol on renal disease 
has been investigated in db/db mice and was shown to reduce inflammatory 
cell infiltration via a reduction in renal epithelial adhesion molecule expression, 
specifically ICAM1147. Allopurinol treatment has also been shown to alleviate 
insulin resistance and hepatic steatosis in Pound mice by reducing oxidative 
stress72,148. The ob/ob mouse strain has been used to determine the effect of 
obesity on UA transporter expression and found that both ob/ob and high fat 
diet fed mice both increased renal expression of URAT1 and ABCG2149. 
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1.8.3 Dietary manipulation 
A diet consisting of a purine rich yeast extract has been used to model 
hyperuricaemia. This model tested the ability of potential therapeutic 
compounds to lower serum uric acid levels150.  
Hyperuricaemia develops alongside obesity and metabolic dysfunction in high 
fat diet models. These models have been used are to test the efficacy of 
cysteine-containing compounds151 and polyphenol-enriched extracts152 to 
reduce metabolic dysfunction .  
A high fructose diet has also been shown to induce hyperuricaemia and 
metabolic dysfunction in rats where the metabolic dysfunction was attributed 
to the increased serum UA promoting endothelial dysfunction153. Metabolic 
dysfunction has been linked to hyperuricaemia in fructose fed rats whereby 
the XOR inhibitor febuxostat has reduced hyperuricaemia, metabolic 
dysfunction and renal disease when used therapeutically154. Additionally, 
another study has shown that arginase inhibition alleviated hypertension in 
fructose fed rats by re-establishing the balance of NO and ROS production 
but had no impact on hyperuricaemia155. This indicates that hyperuricaemia 
may contribute to hypertension and other metabolic disturbances through 
increased arginase activity. 
 
1.9 Aims 
This research aims to develop a better understanding of the role monocytes 
play in hyperuricaemia associated diseases with the ultimate goal of 
determining the potential therapeutic benefits of modulating serum UA to help 
combat human diseases associated with metabolic dysfunction. 
1: To investigate the direct effect of in vitro soluble UA on the inflammatory 
response of human blood monocytes. 
2: To define the in vivo effects of raising and lowering serum UA on systemic 
and monocyte responses to LPS. 
  
 
Chapter 2: 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents and kits 
Reagent/kit Company 
Uric acid detection kit Abcam (Cambidge, UK) 
UASure test strips ApexBio (Taiwan) 
Limulus amebocyte aysate kit 
Associates of Cape Cod (East 
Falmouth, MA) 
Polymorphprep density gradient Axis-Shield (Oslo, Norway) 
ELISA: human IL-12p40, mouse IL-10, 
IL-12p40, IL-6, TNFα 
BD (Auckland, NZ) 
GolgiStop BD Biosciences (Auckland, NZ) 
Propidium iodide BD Biosciences (Auckland, NZ) 
Dc protein assay reagent Bio-Rad (Auckland, NZ) 
Lympholyte M density gradient Cedarlane (Burlington, Canada) 
1-Methoxy-5-methylphenazinium 
methylsulfate (mPMS) 
Dojindo (Kumamoto, Japan) 
2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium 
(WST-1) 
Dojindo (Kumamoto, Japan) 
Bovine serum albumin (BSA) Life Technologies (Auckland, NZ) 
Dihidrorhodamine-123 (DHR-123) Life Technologies (Auckland, NZ) 
Dynabeads untouched human 
monocytes 
Life Technologies (Auckland, NZ) 
Ethylenediaminetetraacetic acid (EDTA) Life Technologies (Auckland, NZ) 
Luminex multiplex cytokine array: 
human IL-10, IL12p40, IL-1β, IL-6, 
TNFα, IL-1Ra, IL-8, CCL2, CCL3, 
CCL4, CCL5, CCL7. 
Life Technologies (Auckland, NZ) 
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ELISA: human IL-1β 
Mabtech (Thomastown, 
Australia) 
Streptavidin-MACS beads 
Miltenyi Biotec (Cologne, 
Germany) 
4-12% Bis-Tris mini gels Life Technologies (Auckland, NZ) 
ELISA: human IL-10, IL-6, TNFα, mouse 
IL-1β 
R and D Systems (Minneapolis, 
MN) 
Adenosine Sigma-Aldrich (Auckland, NZ) 
Adenosine deaminase Sigma-Aldrich (Auckland, NZ) 
β-Nicotinamide adenine dinucleotide 
(NADH) 
Sigma-Aldrich (Auckland, NZ) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Auckland, NZ) 
Epigallocatechin gallate (EGCG) Sigma-Aldrich (Auckland, NZ) 
Lipopolysaccharide (LPS) Sigma-Aldrich (Auckland, NZ) 
Oxonic acid Sigma-Aldrich (Auckland, NZ) 
Phorbol myristate acetate (PMA) Sigma-Aldrich (Auckland, NZ) 
Superoxide dismutase (SOD) Sigma-Aldrich (Auckland, NZ) 
Uric acid Sigma-Aldrich (Auckland, NZ) 
Enhanced chemiluminescent substrate Thermo-Fisher (Auckland, NZ) 
Ultra chemiluminescent substrate Thermo-Fisher (Auckland, NZ) 
KT5720 (Protein kinase A inhibitor) Tocris Bioscience (Bristol, UK) 
PSB1115 (Adenosine A2b receptor 
antagonist) 
Tocris Bioscience (Bristol, UK) 
SLV320 (Adenosine A1 receptor 
antagonist) 
Tocris Bioscience (Bristol, UK) 
VUF5574 (Adenosine A3 receptor 
antagonist) 
Tocris Bioscience (Bristol, UK) 
ZM241385 (Adenosine A2a receptor 
antagonist) 
Tocris Bioscience (Bristol, UK) 
Proteinase inhibitor cocktail Roche (Mannheim, Germany) 
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2.1.2 Antibodies 
Antibody Conjugate Company 
DUSP10 - Abcam (Cambidge, UK) 
NFκB p50 - Abcam (Cambidge, UK) 
NLRP3 - Abcam (Cambidge, UK) 
CD14 PE BD (Auckland, NZ) 
ICAM1 PE BD (Auckland, NZ) 
Annexin V FITC BD Pharmingen (Auckland, NZ) 
CD11b APC-Cy7 BD Pharmingen (Auckland, NZ) 
IL-10 APC BD Pharmingen (Auckland, NZ) 
CD16 PE-Cy7 Biolegend (San Diego, CA) 
CD62L FITC Biolegend (San Diego, CA) 
IκBα - Biolegend (San Diego, CA) 
Ly6C PerCP-Cy5.5 Biolegend (San Diego, CA) 
NFκB p50 - Biolegend (San Diego, CA) 
TLR4 PE Biolegend (San Diego, CA) 
NFκB p65 - Biolenged (San Diego, CA) 
IL-1β - Biovision (Milpitas, CA) 
p-DUSP1 - Cell Signaling (Danvers, MA) 
p-ERK1/2 - Cell Signaling (Danvers, MA) 
p-p38 - Cell Signaling (Danvers, MA) 
poly-IgG - CSL Bioplasma (Melbourne, Australia) 
B220 Biotin eBioscience (San Diego, CA) 
CD11b APC eBioscience (San Diego, CA) 
CD11b PE eBioscience (San Diego, CA) 
CD14 APC eBioscience (San Diego, CA) 
CD162 APC eBioscience (San Diego, CA) 
CD3 Biotin eBioscience (San Diego, CA) 
CD31 PE-Cy7 eBioscience (San Diego, CA) 
Bcl3 - GeneTex (Irvine, CA) 
TBP - GeneTex (Irvine, CA) 
2.4G2 - In-house 
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Caspase1 - Life Technologies (Auckland, NZ) 
ASC - Novus Biologicals (Littleton, CO) 
DUSP1 - Santa Cruz Biotechnology (Dallas, TX) 
Mouse 2o HRP Santa Cruz Biotechnology (Dallas, TX) 
Rabbit 2o HRP Santa Cruz Biotechnology (Dallas, TX) 
α-tubulin - Sigma-Aldrich (Auckland, NZ) 
β-actin - Sigma-Aldrich (Auckland, NZ) 
 
 
2.1.3 Commercial buffers and media 
Buffer/Media Company 
Hank’s balanced salt solution, 
Ca2+ and Mg2+ free (HBSS) 
Life Technologies (Auckland, NZ) 
RPMI-1640 Life Technologies (Auckland, NZ) 
Penicillin-Streptomycin Life Technologies (Auckland, NZ) 
Glutamax Life Technologies (Auckland, NZ) 
Dulbecco’s phosphate 
buffered saline (DPBS) 
Life Technologies (Auckland, NZ) 
4x sample loading buffer Life Technologies (Auckland, NZ) 
10x sample reducing buffer Life Technologies (Auckland, NZ) 
MES running buffer Life Technologies (Auckland, NZ) 
RBC lysis buffer Qiagen (Germantown, MD) 
 
2.1.4 In-house buffers and media 
Salts and buffer constituents were sourced from Sigma-Aldrich (Auckland, 
NZ) unless stated otherwise in sections 2.1.1 or 2.1.3. 
 
Autologous human serum (ahs)RPMI 
RPMI-1640 with 100units/ml penicillin, 100µg/ml streptomycin, 1x glutamax 
and 5% heat inactivated autologous human serum. 
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Serum free (sf)RPMI 
RPMI-1640 with 100units/ml penicillin, 100µg/ml streptomycin, 1x glutamax. 
 
FACS buffer 
DPBS with 0.1% BSA and 0.01% sodium azide. 
 
Saponin buffer 
DPBS with 0.1% saponin, 0.1% FBS and 0.1% sodium azide. 
 
Annexin V binding buffer 
Distilled water with 10mM HEPES, 140mM NaCl and 2.5mM CaCl2. Adjust pH 
to 7.4 with NaOH. 
 
Cytosolic protein isolation buffer 
Distilled water with 10mM HEPES, pH7.9, 1.5mM MgCl2, 10mM KCl, 10mM 
NaMoO4, 1x proteinase inhibitor cocktail, 20mM β-glycerophosphate, 2mM 
Na3VO4 and 1mM PMSF. 
 
Nuclear protein isolation buffer  
Distilled water with 20mM HEPES, pH7.9, 1.5mM MgCl2, 420mM NaCl, 10mM 
Na2MoO4, 25% glycerol, 1x proteinase inhibitor cocktail, 20mM β-
glycerophosphate, 2mM Na3VO4 and 1mM PMSF. 
 
Tris-Glycine buffer 
Distilled water with 0.3% Tris, 1.44% glycine and 20% MeOH. 
PBS-Tween 
DPBS with 0.1% Tween20. 
With addition of 5% non-fat milk powder for western blot blocking buffer. 
With addition of 2% BSA for western blot antibody dilution buffer. 
 
Automacs running buffer 
DPBS with 1% heat inactivated FBS and 0.5mM EDTA. 
 
Chapter 2: Materials and Methods 
 
28 
ELISA wash buffer 
DPBS with 0.05% Tween20. 
 
Bioplex buffer 
DPBS with 0.1% BSA, 0.05% Tween20, 0.005% sodium azide, 2.5mM EDTA. 
 
0.1M Carbonate Buffer 
Distilled water with 85mM NaHCO3 and 15mM Na2CO3, pH to 10.5 with NaOH. 
 
 
2.1.5 Preparation of monosodium urate (MSU) crystals 
45ml distilled water with 300µl 5M NaOH was heated to gentle boil on a 
heating/stirring block. Under constant stirring 250mg uric acid was added 
slowly and stirring was continued until completely dissolved. Volume was 
adjusted to 50ml with distilled water and the solution was cooled to 50oC. The 
solution was then filtered through a 0.2µm filter and reboiled. Under sterile 
conditions 1ml 5M NaOH was added without stirring and the solution was left 
undisturbed for 7 days at room temperature to allow for crystallisation to occur. 
Crystals were washed with ethanol then acetone and allowed to dry before 
being checked for size and shape. MSU crystals were examined by light 
microscopy and were found to be 5-25µm long with a needle like shape and 
birefringent under polarised light. 
 
2.1.6 Endotoxin testing 
Endotoxin levels of uric acid, oxonic acid, allopurinol and MSU preparations 
were determined using the Limulus Amebocyte Lysate assay. For in vitro 
experiments cells were exposed to <0.5 EU/ml. For in vivo experiments mice 
were exposed to <5 EU/kg. 
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2.2 Human Methods 
2.2.1 Clinical study design 
15 patients >18yrs of age with gout as defined by the American Rheumatism 
Association Preliminary Classification Criteria and the Wallace Criteria156 were 
recruited from the Christchurch Hospital Rheumatology Service. This study 
was approved by the New Zealand Multi-Region Ethics Committee 
(MEC/11/06/060) and registered with the Australian and New Zealand Clinical 
Trials Registry ACTRN 12613000114741. All participants provided written 
informed consent. The decision to commence allopurinol was made by the 
treating rheumatologist. The starting dose of allopurinol was 50mg daily for 
patients with creatinine clearance (CrCL)<60ml/min and 100mg/day for 
patients with a CrCL>60mls/min. The low dose reduces the risk of allopurinol 
hypersensitivity syndrome and the precipitation of an acute gout flare83. Blood 
was taken directly before starting treatment, one day after the first allopurinol 
dose and 28 days after starting treatment. At each time point 60ml of venous 
blood was taken and processed immediately to isolate blood monocytes 
(section 2.2.2) for subsequent analyses.  
Patient sample size calculation was based on one cytokine, CCL2, as this 
was the key cytokine of interest. Our previous data indicated an important 
difference in serum CCL2 is 220 pg/ml (R Grainger, PhD thesis).  The paired 
standard deviation for repeated measures t-test is not known, nor published in 
the literature. Therefore, this pilot study could be used to calculate the paired 
standard deviation of difference in cytokine level before and after urate-
lowering therapy. The usual sample size for such a study is 12 to 15 subjects. 
 
2.2.2 Isolation of human blood monocytes 
Blood from the clinical study patients and a separate study involving healthy 
normouricaemic donors (CEN/08/11/062) was collected by venepuncture into 
K3-EDTA vacutainers and spun at 840g for 10min to separate the plasma. 
Plasma was aspirated, pooled and spun at 840g for 10min. The pellet was 
discarded and the plasma was heat inactivated at 57oC for 30min, spun at 
840g for 10min to pellet the coagulated proteins and the autologous human 
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serum (ahs) was aspirated for preparation of ahsRPMI and subsequent cell 
culture. 
The separated blood cells were diluted two-fold with HBSS and 10-11ml of 
this mixture was layered over 3ml polymorphprep in a 15ml falcon tube. The 
blood preparation was then spun at 680g for 45min with no brake to separate 
the PBMC (top layer) from the PMN (middle layer) and the RBC (bottom layer). 
PBMC were aspirated, washed with 40ml HBSS and spun at 450g for 5min. 
PBMC where then washed and spun at 300g for 10min to remove platelets. 
Residual RBC were lysed by suspending the washed PBMC in 5-10ml RBC 
lysis buffer and incubating at 37oC for 10min then PBMC were washed once 
more in 40ml HBSS and spun at 300g for 10min. 
Human blood monocytes were isolated from the PBMC using Dynabeads 
Untouched Human Monocytes. Isolated human blood monocytes were 
resuspended in ahsRPMI at 2 x 106 cells/ml for analysis. 
 
2.2.3 In vitro monocyte activation assays 
Isolated human blood monocytes were pre-incubated for 1hr with 
combinations of UA and the agonists, antagonists or enzymes being 
investigated then stimulated with LPS (100ng/ml) for cytokine production 
(18hr) or protein expression (up to 1hr). Cell density was 1 x 106/ml. 
Cytokine and chemokine production in culture supernatants was analyzed by 
ELISA or multiplex cytokine array. Protein expression was assessed by 
western blotting. 
 
2.2.4 Monocyte photography and cluster analysis 
Isolated human blood monocytes were photographed in flat bottom 96 well 
plates using an Olympus IX51 inverted microscope (Olympus, Auckland, NZ). 
Monocyte cluster size was measured using ImageJ software. The area of 
each cluster within a field of view was estimated using the ‘oval’ selection tool 
and the ‘measure’ function to produce an area measurement. The mean 
cluster area in each treatment group was then normalised to cluster area of 
Chapter 2: Materials and Methods 
 
31 
LPS alone. The number of monocyte clusters in each field of view for each 
treatment was also counted.  
 
2.3 Mouse methods 
2.3.1 Animal husbandry 
Male C57BL/6 (C57) and UrahPlt2/Plt2 (PLT2) mice were housed in the 
Biomedical Research Unit, Malaghan Institute of Medical Research 
(Wellington, NZ) under specific pathogen free conditions with a 12hr light-dark 
cycle. Experimental mice were aged between 6-12 weeks. All experimental 
procedures were undertaken with ethical approval from the Victoria University 
of Wellington Animal Ethics Committee. 
 
2.3.2 Mouse model of acute hyperuricaemia 
Oxonic acid (OA) is a uricase inhibitor that prevents the breakdown of UA in 
the mouse liver157. Combining UA with OA will ensure a rapid rise in serum 
UA and a prolonged state of hyperuricaemia.  
OA was suspended in PBS. UA was dissolved in PBS by addition of 10M 
NaOH then the pH was brought down to 10.5 with 2M HCl. The UA solution 
was filter sterilised before administration. 
C57 mice were injected i.p. with oxonic acid (300mg/kg, 30min) followed by i.v. 
injection of soluble UA (12mg/kg, 1hr) (figure 2.1A).  
 
2.3.3 Mouse models of urate-lowering therapy (ULT) 
To investigate the effect of lowering serum UA in vivo on systemic 
inflammation two different methods of ULT were used. Allopurinol was 
dissolved in carbonate buffer, pH 10.5, by warming to 37oC. Rasburicase was 
diluted in PBS. C57 or PLT2 mice were injected i.v. with allopurinol (30mg/kg, 
3hr) or rasburicase (0.8mg/kg, 3hr) (figure 2.1B). 
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2.3.4 LPS model of systemic inflammation 
To induce a non-lethal systemic inflammatory cytokine response C57 and 
PLT2 mice were injected i.v. with a low dose of LPS (40µg/kg, 1hr) following 
induction of acute hyperuricaemia or ULT with allopurinol or rasburicase 
(figure 2.1). 
 
2.3.5 Murine blood processing 
Blood was taken from the submandibular facial vein using a 4mm lancet 
(MEDIpoint, Mineola, NY). Blood was collected into microtubes containing 
10µl 0.5M EDTA and centrifuged immediately at 10,000g for 10min. Plasma 
was removed and frozen at -80oC for subsequent cytokine and UA 
measurement. 
 
2.3.6 Murine spleen processing 
Spleens were dissected from mice, passed through a 40µM cell strainer to 
create a single cell suspension, washed with 10ml sfRPMI and spun at 450g 
for 5min. The cell pellet was resuspended in 5ml sfRPMI. An aliquot was 
taken at this stage for analysis of intracellular cytokine production by flow 
cytometry (section 2.4.2). 
 
2.3.7 AutoMACS purification of splenic monocytes 
5ml of splenic cell suspension was layered over 4ml Lympholyte M density 
gradient and centrifuged for at 1200g for 20min. The upper cell layer was 
aspirated, washed in PBS and spun at 450g for 5min then resuspended in 1ml 
automacs running buffer. Cells were counted and 1µl CD3-biotin and B220-
biotin per 107 cells was added followed by incubation for 15min at 4oC. Cells 
were then rinsed twice in 5ml automacs running buffer and spun at 450g for 
5min then resuspended in 200µl automacs running buffer per 107 cells. 10µl 
streptavidin MACS beads were added per 200µl then incubated with rolling 
and tilting for 30min at 4oC. Cells were then rinsed in 5ml automacs running 
buffer and spun at 450g for 5min then resuspended in 2ml automacs running 
buffer, passed through a 30µM cell strainer to remove any aggregates and 
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run through an AutoMACS (Miltenyi Biotec, Cologne, Germany) to remove 
CD3 positive and B220 positive cells. The negative fraction was collected and 
prepared for cytosolic and nuclear protein isolation as described in section 
2.5.1. 
 
         
Figure 2.1 Mouse models of acute hyperuricaemia, urate-lowering therapy 
and systemic inflammation.  
A: Mice were injected with OA i.p. (300mg/kg) then UA i.v. (12mg/kg) followed by 
LPS i.v. (40µg/kg). B: Mice were injected i.v. with allopurinol (30mg/kg) or 
rasburicase (0.8mg/kg) followed by LPS i.v. (40µg/kg). OA = oxonic acid, UA = uric 
acid, LPS = Lipopolysaccharide, ULT = urate-lowering therapy. 
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2.4 Flow cytometry 
2.4.1 Surface staining for flow cytometry 
Cells were distributed into 96 well plates for flow cytometry staining then 
washed with 200µl FACS buffer and spun at 450g for 5min. Blocking 
antibodies for human (poly-IgG) or mouse (FcγRII clone 2.4G2) were added to 
prevent non-specific binding, followed by a FACS buffer wash step. Antibody 
master mixes were added and incubated for 20min. Cells were washed again 
in 200µl FACS buffer then fixed in 4% neutral buffered formalin for 20min. 
Following fixation cells were washed in 200µl FACS buffer, then resuspended 
in 200µl FACS buffer for analysis. 
 
2.4.2 Intracellular staining for flow cytometry 
For analysis of intracellular cytokine production by flow cytometry 106 
splenocytes were cultured for 4hr (37oC, 5%CO2) with GolgiStop (1:1000 
dilution) then stained for cell surface markers (section 2.4.1). Following 
fixation the cells were washed in 200µl Saponin buffer to permeabilise and 
spun at 450g for 5min, then incubated with antibody master mixes prepared in 
Saponin buffer for 30-60min. The cells were washed in 200µl Saponin buffer 
and spun at 450g for 5min then resuspended in FACS buffer for analysis. 
 
2.4.3 Cell death analysis 
Monocytes were washed in 200µl annexin-V binding buffer and spun at 450g 
for 5min then labelled with the apoptosis marker annexin-V FITC for 20min. 
Cells were washed again with 200µl annexin-V binding buffer then 
resuspended in FACS buffer for flow cytometry. Directly before analysis the 
cell death marker propidium iodide (250ng/ml) was added. 
 
2.4.4 Intracellular reactive oxygen species 
To measure intracellular production of reactive oxygen species (ROS) 
monocytes were pre-incubated for 5min with the ROS specific dye 
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dihydrorhodamine (DHR)-123 (0.5µM) (37oC, 5% CO2) then stimulated with 
LPS (100ng/ml) or PMA (5ng/ml) for 30min and analysed by flow cytometry.  
 
2.4.5 Flow cytometry equipment 
Flow cytometry was performed on a FACSCalibur or LSR-II (BD, Auckland, 
NZ) and data was analyzed using FlowJo software (Tree Star, Ashland, OR). 
 
2.5 Western blotting 
2.5.1 Cytosolic and nuclear protein isolation 
Cytosolic and nuclear protein was isolated from human blood monocytes and 
murine splenic monocytes using in house cytosolic protein isolation buffer and 
nuclear protein isolation buffer.  
Cells were washed three times in ice cold PBS and all liquid was removed by 
aspiration. 40-60µl of cytosolic protein isolation buffer was added to each cell 
pellet and transferred to microcentrifuge tubes for 20min on ice. 2.5µl 10% 
igepal was added to each sample then incubated on ice for 2min. Samples 
were centrifuged for 2min at 4oC, 20,000g and the cytosolic protein was 
removed and stored at -80oC. The pellet was then washed with 500µl ice cold 
PBS and spun for 2min at 4oC, 20,000g. The PBS was aspirated and the 
nuclear pellet was resuspended in 20µl nuclear protein isolation buffer and 
incubated for 30min in ice. Samples were spun for 10min at 4oC, 20,000g and 
the nuclear protein removed and stored at -80oC. 
 
2.5.2 Determining protein concentration 
The concentration of cytosolic or nuclear protein was measured using the 
Lowry method158 with the Dc Protein Assay Reagent kit. Protein was diluted 3-
fold in MilliQ water then 5µl of each sample or BSA standard was aliquoted in 
duplicate into a flat bottom 96 well plate. A standard curve of 0, 0.25, 0.5, 1, 2 
and 4mg/ml BSA was used. Dc protein assay reagents A and S were mixed at 
a 50:1 ratio respectively. 25µl of this mixture was added to each sample and 
standard well. 200µl Dc protein reagent B was added to each well and mixed 
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thoroughly. The reaction was incubated for 15min at room temperature then 
the absorbance was read at 750nm with a Versamax microplate reader. 
Linear regression was used to calculate sample protein concentrations from 
the standard curve. 
 
2.5.3 Gel electrophoresis 
Equal amounts of protein (10-20µg) were mixed with MilliQ water, 4x loading 
buffer and 10x reducing buffer to produce samples of equal volume. These 
were then heated for 6min at 95oC in a dry heat block then loaded into 
NuPAGE Novex 4-12% Bis-Tris mini gels with Magic Mark and Novex 
prestained protein ladders as molecular weight markers. The gels were run at 
200V in MES running buffer for 40-60min. This voltage and running time gave 
good separation in the 30-70kD range where the majority of my proteins of 
interest were. 
 
2.5.4 Western blotting 
Protein was transferred from the gel to a PVDF membrane (0.2µm pore size, 
BioRad, Auckland, NZ) for 2hr at 300mA using a western blot transfer 
cassette and Tris-Glycine buffer. After transfer membranes were blocked with 
western blot blocking buffer (PBS-Tween with 5% non-fat milk powder) for 1hr 
then washed with PBS and incubated with primary antibodies diluted in 
western blot antibody dilution buffer (PBS-Tween with 2% BSA) overnight at 
4oC. Membranes were washed 3 times with PBS-Tween then incubated with 
HRP-linked secondary rabbit or mouse antibodies diluted in western blot 
antibody dilution buffer for 2hr. Membranes were washed 3 times with PBS-
Tween and once with PBS then incubated for 2-5min with Enhanced or Ultra 
Chemiluminescent Substrate. Membranes were photographed with a Gel 
Logic 4000 Pro (Carestream, Rochester, NY). 
β-actin was used as a loading control for both cytoplasmic and nuclear protein. 
β-actin was compared to Tata Binding Protein (TBP) for nuclear protein 
loading and found to have an equivalent loading pattern. α-tubulin was used 
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to test nuclear protein extracts for cytoplasmic protein contamination as α-
tubulin is not normally present in the nucleus of cells.  
 
2.5.5 Western blot densitometry 
The density of western blot bands was calculated using ImageJ software. 
Lanes were selected with the rectangle tool, which produces a peak for each 
band in the lane. The peaks were closed off with the line tool to remove any 
background reading and the area of each peak was measured using the wand 
tool. These area measurements were then converted into a percentage of the 
total area of the combined peaks using the label peaks function. The 
percentages of each protein measured were normalised to the control band 
(day 0) then normalised again to the corresponding loading control to produce 
a measurement relative to day 0 (set at 1) and normalised to the loading 
control to account for any differences in protein loading. 
 
2.6 General methods 
2.6.1 Measurement of serum UA 
Murine serum UA levels were measured using the Uric Acid Detection Kit. 
20µl serum sample was mixed with 30µl UA assay buffer in a 96-well flat-
bottomed plate. Standards of 0, 0.8, 1.6, 2.4, 3.2 and 4nm/well UA diluted in 
50µl UA assay buffer were set up for each assay. A reaction mixture of 46µl 
UA assay buffer, 2µl UA Probe and 2µl UA Enzyme Mix was prepared for 
each sample and standard. 50µl reaction mixture was added to each sample 
and standard and the reaction was incubated at 37oC for 30min, protected 
from light. The fluorescence was measured at Ex/Em = 544/590 using a 
FLUOstar OPTIMA microplate reader (BMG Labtech, Ortenberg, Germany). 
Linear regression was used to calculate serum UA concentrations from the 
standard curve.  
Healthy human serum UA levels were measured from whole blood using a 
UASure blood uric acid monitoring system and UASure test strips. For the 
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clinical study patient serum UA was measured by Canterbury Health Labs 
(Christchurch, NZ). 
 
2.6.2 Chemical assay for anti-oxidant activity 
This assay measures the transfer of electrons from NADH via mPMS to WST-
1 by measuring the absorbance of reduced WST-1 at 450nm. Anti-oxidant 
activity of soluble UA can be measured by a decrease in absorbance at 
450nm compared to control159. 
A reaction mixture containing 100µM NADH, 3µM mPMS and 349µM WST-1 
was prepared in HBSS in 96well flat bottom plates with the addition of soluble 
UA (0.1-0.7mM). SOD (0.1-1000µM) and EGCG (0.05-50µg/ml) were used as 
positive controls for anti-oxidant activity. The reaction was carried out for 
30min at 37oC then WST-1 absorbance was measured at 450nm with a 
Versamax microplate reader (Molecular Devices, Sunnyvale, CA). 
 
2.7 Statistical analysis 
Two-way ANOVA with Bonferroni post-test was used to evaluate significance 
for time course and titration experiments involving multiple variables. One-way 
ANOVA with Bonferroni post-test was used when more than two variables 
were being compared at a single time point. Student’s t-test was used when 
only two variables were used at a single time point. Paired t-test was used to 
compare clinical study data before and after ULT. Linear regression and 
Pearson’s correlation coefficient were used to evaluate patient data in 
comparison to their serum UA levels. Statistical analyses were performed with 
Prism (GraphPad Software, San Diego, CA). 
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3 In vitro hyperuricaemia 
3.1 Introduction  
The immunological effects of soluble uric acid (UA) on human blood 
monocytes have not yet been thoroughly investigated.  
In other cell types soluble UA has been shown to have stimulatory effects. In 
vascular smooth muscle cells129, adipocytes71 and pancreatic β cells67 soluble 
UA activates MAP kinase signalling pathways and NFκB family transcription 
factors. Additionally, the Harper group has shown that human neutrophil 
superoxide production, following ex vivo monosodium urate (MSU) stimulation, 
is positively associated with serum UA levels160. These studies demonstrate 
that UA has the ability to modulate signalling pathways that contribute to 
inflammatory responses. 
In a clinical setting, hyperuricaemia correlates with increased monocyte 
numbers in the blood in patients with gout and asymptomatic 
hyperuricaemia128 and patients with coronary artery disease161. However, 
these studies do not address whether the increase in monocyte numbers 
translates to differences in monocyte function or disease state. One study 
shows that monocytes from hyperuricaemic haemodialysis patients have 
higher rates of apoptosis than healthy controls162. This increased monocyte 
apoptosis is attributed to a direct effect of soluble UA on monocytes as 
apoptosis is inhibited by the addition of rasburicase, which breaks down the 
UA. 
These studies demonstrate that soluble UA is a ubiquitous regulator of cellular 
function but there remains a dearth of research into the direct effect of soluble 
UA on immune cell function. The ability of UA to alter the function of other cell 
types provides a rationale for investigating the effects of UA on monocyte 
function.  
Given that blood monocytes are directly exposed to soluble UA in the 
circulation, changes in serum UA could have an immediate effect on 
monocyte responses to immune challenge. Previously, our group carried out 
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an observational clinical study investigating the effect of serum UA levels on 
circulating innate immune cells in healthy controls versus subjects with 
hyperuricaemia160. One aspect of this study examined the ex vivo response of 
the participants’ blood monocytes following stimulation with LPS. 
Hyperuricaemia is the main risk factor for gout and gout is a highly 
inflammatory disease. Based on this relationship we had hypothesised that 
monocytes from hyperuricaemic participants would be more pro-inflammatory 
than those from normouricaemic controls. Surprisingly, there was a negative 
correlation between participants’ serum UA levels and production of pro-
inflammatory cytokines by monocytes stimulated ex vivo with LPS (figure 3.1). 
This negative correlation suggested that UA was having a suppressive effect 
on monocyte cytokine production. It also provided a rationale to investigate 
the direct effect of soluble UA, by modelling hyperuricaemia in vitro, on the 
phenotype and function of human blood monocytes. 
 
 
Figure 3.1 Ex vivo monocyte cytokine production negatively correlates with 
serum UA levels.  
Human blood monocytes isolated from participants with hyperuricaemia and 
normouricaemia (n=90) were stimulated with LPS (100ng/ml) for 18hr. Cytokine 
production was measured by multiplex bead array and plotted against participants’ 
serum UA levels. * p<0.05, ** p<0.01. Spearman’s correlation coefficient.  
 
 
3.2 Aim 
The aim of this chapter was to study the direct effect of soluble UA on blood 
monocyte responses to LPS in vitro and investigate possible mechanisms of 
action for soluble UA.  
! !"# !"$ !"% !"&!
#!!
$!!
%!!
&!!
'!!!
()*+,-./-0,12
345
'
-06
78,
92
:-*-;-5!"##<
=>
?
-0@
78,
92
! !"# !"$ !"% !"&
!
'
#
A
$
B ::-*-;-5!"#&$C
()*+,-./-0,12
! !"# !"$ !"% !"&!
B
'!
'B
#!
#B
()*+,-./-0,12
345
%-0
@7
8,
92
:-*-;-5!"#B!%
Chapter 3: In Vitro Hyperuricaemia 
 
41 
3.3 Results 
3.3.1 Monocyte viability and soluble UA 
Apoptosis is a mechanism of programmed cell death that is used by the body 
to remove cells in a safe and non-inflammatory manner. It has been shown 
that after a 96hr exposure, soluble UA can increase apoptosis in a human 
monocytic cell line (U937) and human peripheral blood mononuclear cells162. 
Therefore, it was possible that exposure to high levels of UA in the serum was 
increasing monocyte cell death in our system, resulting in decreased pro-
inflammatory cytokine production. Therefore, I tested the effect of soluble UA 
on human monocyte viability at 18hr.  
I isolated blood monocytes from healthy, normouricaemic volunteers and 
stimulated the cells with LPS in the presence or absence of soluble UA for 
18hr. I then measured cell viability by flow cytometry using the apoptosis 
marker annexin V and the cell death marker propidium iodide. UA had no 
effect on monocyte viability, defined as annexin V and propidium iodide 
negative, with or without LPS stimulation (figure 3.2). This suggested that the 
decrease in monocyte cytokine production in figure 3.1 was not due to 
increased monocyte cell death, indicating that soluble UA may be suppressing 
the monocyte cytokine response to LPS. 
 
Figure 3.2 Monocyte viability is unaffected by UA.  
Human blood monocytes were pre-treated with or without UA (0.3 or 0.6mM) for 1hr 
then LPS (100ng/ml) for 18hr. Cells were stained with propidium iodide and annexin 
V and analysed by flow cytometry. Live cells are defined as annexin V negative and 
PI negative. Results are mean with SEM of triplicate measurements and are 
representative of two independent experiments from different volunteers. 
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3.3.2 Monocyte cytokine production 
Next I investigated the effect of soluble UA on monocyte cytokine production. 
To confirm that elevated serum UA could directly suppress the cytokine 
response of circulating human blood monocytes I treated monocytes from 
healthy normouricaemic volunteers ex vivo with physiological levels of UA  
(0.3mM, normal and 0.6mM, hyper). UA alone had no effect on monocyte 
cytokine production (figure 3.3A-C). In LPS treated monocytes 0.6mM UA 
decreased IL-1β, TNFα and IL-6 compared to LPS alone (figure 3.3A-C). 
These results showed that soluble UA was having a direct effect by 
suppressing LPS-induced monocyte cytokine production and confirmed the 
negative clinical correlation between serum UA levels and monocyte cytokine 
production.  
 
 
Figure 3.3 UA reduces LPS-induced pro-inflammatory cytokines and 
enhances IL-10.  
Human blood monocytes were pre-treated with or without UA (A-C: 0, 0.3 and 
0.6mM) for 1hr then stimulated with LPS (100ng/ml) for 18hr. A: IL-1β, B: TNFα and 
C: IL-6 production was assessed by multiplex cytokine bead array. *p<0.05, **p<0.01. 
Two-way ANOVA with Bonferroni post-test. Results are mean with SEM of triplicate 
measurements and are representative of five independent experiments from 
individual volunteers. 
 
 
3.3.3 Monocyte LPS signalling machinery 
LPS signals through the LPS receptor complex at the cell surface and two 
major components of this complex are CD14 and TLR4. CD14 binds LPS in 
conjunction with LPS binding protein and TLR4 is a DAMP receptor that 
translates LPS-CD14 binding into the downstream intracellular signalling 
cascade163. I hypothesised that UA could be altering the surface expression of 
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CD14 or TLR4 and thereby altering downstream signalling. To test this 
hypothesis I measured CD14 and TLR4 expression on monocytes after 18hr 
incubation with UA and/or LPS. LPS enhanced CD14 expression (figure 3.4A) 
but UA did not change surface expression of CD14 or TLR4 with or without 
LPS stimulation (figure 3.4A-B). Hence, UA was not altering monocyte 
cytokine responses via changes to the LPS receptor machinery. 
 
Figure 3.4 CD14 and TLR4 expression is unaffected by UA.  
Human blood monocytes were pre-treated with or without UA (0.6mM) for 1hr then 
stimulated with LPS (100ng/ml) for 18hr. A: CD14 and B: TLR4 expression was 
measured by flow cytometry. Results representative of three independent 
experiments from individual volunteers. 
 
 
3.3.4 Intracellular reactive oxygen species (ROS) generation during LPS 
stimulation 
Next I investigated the intracellular effects of UA on human blood monocytes. 
Serum UA is currently considered one of the main sinks for circulating ROS9 
and reactive nitrogen species (RNS)164,165. However, the protective function of 
soluble UA and its role as an important circulating anti-oxidant is being 
challenged by more recent publications that report increased serum UA as 
having an adverse effect on cancer outcomes166 and adipocyte homeostasis71. 
ROS can promote inflammatory cytokine production167,168. Therefore, I 
hypothesised that UA was scavenging monocyte intracellular ROS and 
thereby altering the downstream cytokine signalling. To test the anti-oxidant 
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effect of UA I measured intracellular monocyte ROS with dihydrorhodamine-
123 (DHR-123), which reacts with ROS to produce a fluorescent product that 
can be measured by flow cytometry. Treatment with UA, LPS or the 
combination of both did not change the levels of monocyte intracellular ROS 
(figure 3.5) indicating that UA was not altering cytokine signalling by 
scavenging intracellular ROS. 
 
 
Figure 3.5 Monocyte intracellular ROS is unaffected by UA.  
Human blood monocytes were pre-treated with or without UA (0.6mM) for 1hr then 
stimulated for 30min with LPS (100ng/ml) or PMA (5ng/ml). Intracellular ROS 
production was measured by flow cytometry. Results are representative of three 
independent experiments from individual volunteers. 
 
 
3.3.5 Testing UA as an electron scavenger 
To test the direct anti-oxidant capacity of UA I used a cell free chemical assay 
where electrons are passed from NADH via methoxy-PMS to a water soluble 
tetrazolium salt (WST-1)159. The assay measures the oxidation of NADH, 
through the reduction of WST-1 to a coloured compound, which can be 
inhibited by anti-oxidants. I measured the reduction of WST-1 in the presence 
of soluble UA (0.1-0.7mM), using superoxide dismutase (SOD) and the green 
tea extract epigallocatechin-3-gallate (EGCG), a known dietary anti-oxidant169, 
as positive controls for electron scavenging. UA had no effect on WST-1 
reduction at any of the concentrations tested (figure 3.6A), while both SOD 
and EGCG inhibited the reduction of WST-1 in a concentration dependent 
manner (figure 3.6B).  
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UA had no effect on both intracellular monocyte ROS and a cell free redox 
assay confirming that the suppression of LPS-induced monocyte cytokines by 
UA was not mediated by scavenging ROS. 
 
 
Figure 3.6 Soluble UA is not an electron scavenger.  
(A) UA and (B) vehicle (DMSO), EGCG or SOD were titrated into a cell free redox 
assay measuring the chemical reduction of WST-1. Absorbance was measured at 
450nm. Highest concentrations of EGCG and SOD (100) were 1000µM and 50µg/ml 
respectively. Results are mean with SEM of triplicate measurements and are 
representative of two independent experiments. 
 
 
3.3.6 NFκB signalling pathway 
Downstream of LPS signalling is the NFκB complex, which in monocytes is 
involved in regulation of cytokine transcription. The NFκB family of 
transcription factors are important for both pro- and anti-inflammatory cytokine 
production and function as hetero- and homodimers of the different subunits. 
(figure 3.7) The p65/p50 heterodimer is a transcription factor for many pro-
inflammatory cytokines while the p50/p50 homodimer is inhibitory of p65/p50 
and is itself a transcription factor for IL-10170,171. Concurrent experiments 
performed by the Harper group (unpublished data) showed that UA had 
differential effects on nuclear translocation of NFκB subunits in monocytes 
stimulated with LPS. UA decreased LPS-induced nuclear translocation of 
NFκB p65 and enhanced early translocation of p50 (appendix 7.1). This 
indicated a predominance of the p50 subunit and perhaps more p50/p50 
homodimer in the nucleus following UA exposure.  
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Figure 3.7 LPS-induced monocyte pro- and anti-inflammatory cytokine 
production via NFκB.  
Following LPS stimulation NFκB p65/p50 signalling initiates pro-inflammatory 
cytokine transcription. IκBα production restricts inflammatory NFκB p65/p50 
signalling and reduces pro-inflammatory cytokine production. NFκB p50/p50 nuclear 
translocation promotes IL-10 production and inhibits pro-inflammatory cytokines.   
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NFκB p65/p50 is sequestered and inactive in the cytoplasm when bound by 
IκBα, which is quickly degraded upon activation by LPS, releasing the 
p65/p50 heterodimer and allowing it to translocate to the nucleus. IκBα levels 
are gradually replenished after an initial activation signal to prevent prolonged 
NFκB activation172.  
To determine if the reduced nuclear NFκB p65 in the presence of UA was due 
to altered IκBα expression I analysed monocyte IκBα levels by western blot. 
LPS treatment resulted in a rapid loss of IκBα levels at 15min in both control 
and UA treated monocytes. However, UA increased the recovery of IκBα 
levels at 30 and 60min post-LPS (figure 3.8). This indicated that UA could be 
limiting nuclear translocation of the pro-inflammatory p65/p50 heterodimer via 
more rapid replenishment of IκBα, after LPS mediated degradation. Altering 
the p65 to p50 ratio could be one mechanism through which UA inhibited 
LPS-induced pro-inflammatory cytokine production (figure 3.3). 
 
 
 
Figure 3.8 IκBα  levels return faster with UA treatment after LPS stimulation.  
Western blot of IκBα from human blood monocytes pre-treated with or without UA 
(0.6mM) for 2hr and 15, 30 or 60min with LPS (100ng/ml). β-actin was used as a 
loading control. Results are representative of three independent experiments from 
individual volunteers. 
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3.3.7 Anti-inflammatory cytokine production 
NFκB p50 nuclear translocation was increased by UA in LPS treated 
monocytes (appendix 7.1) and the p50/p50 homodimer, while being inhibitory 
of p65/p50 gene transcription is also a transcription factor for IL-10, a 
canonical anti-inflammatory cytokine171.  
Therefore, I wanted to determine whether UA could enhance monocyte IL-10 
production. I treated monocytes with UA then stimulated them with LPS and 
measured production of IL-10 and IL-12p40. UA alone did not induce 
monocyte IL-10 production but UA and LPS treatment increased monocyte IL-
10 compared to LPS alone (figure 3.9A). In comparison, treatment with UA 
decreased production of the pro-inflammatory cytokine IL-12p40 in LPS-
treated monocytes (figure 3.9B). 
 
Figure 3.9 UA enhances LPS-induced IL-10 and reduces IL-12p40.  
Human blood monocytes were pre-treated with or without UA (C=0 and UA=0.6mM) 
for 1hr then stimulated with LPS (100ng/ml) for 18hr. A: IL-10 and B: IL12p40 
production in culture supernatant was assessed by ELISA. *p<0.05, **p<0.01. 
Student’s t-test. Results are mean with SEM of triplicate measurements and are 
representative of six independent experiments from individual volunteers. 
 
3.3.8 Involvement of MAP kinases and their regulation by UA 
Concurrent research within our group found that monocytes stimulated with 
LPS in the presence of UA accelerated the dephosphorylation of p38 and 
ERK1/2 MAP kinases, compared with LPS alone (appendix 7.2). MAP kinase 
phosphorylation and activity is tightly controlled, in part by the action of dual 
specific phosphatases (DUSP)173 (figure 3.10).  
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Figure 3.10 LPS-induced monocyte pro-inflammatory cytokine production via 
MAP kinase signalling.  
Following LPS stimulation p38 and ERK1/2 MAP kinases are phosphorylated and 
activated. DUSP10 can dephosphorylate p38 and ERK1/2 MAP kinase to deactivate 
them and reduce pro-inflammatory cytokine production but is inhibited by ASC.  
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DUSP10 has been shown to be an important homeostatic regulator of LPS-
induced inflammation, whereby DUSP10 deficiency results in far greater 
inflammatory responses and susceptibility to sepsis174. In turn, DUSP10 
expression is regulated by apoptosis associated speck-like protein containing 
a CARD (ASC) although the precise mechanism of interaction between 
DUSP10 and ASC is still unclear175. ASC is an adapter protein best 
characterised for its role in bringing together the NLRP3 inflammasome, the 
control switch for IL-1β maturation114. However, there is increasing evidence 
that ASC has NLRP3 inflammasome independent functions such as 
promoting antigen uptake and chemotaxis176 and controlling IL-10 production 
in CD4+ T cells177. 
Therefore, I investigated monocyte ASC and DUSP10 expression by western 
blotting to see if these signalling molecules were involved in regulation of the 
observed MAP kinase dephosphorylation and increased IL-10 production. 
I treated monocytes with or without UA for 2hr and stimulated with LPS for up 
to 1hr. UA alone reduced monocyte ASC levels and LPS alone reduced 
monocyte ASC over time (figure 3.11A). DUSP10 levels were increased in UA 
treated monocytes and decreased following stimulation with LPS in both 
control and UA treated monocytes (figure 3.11A). I then treated monocytes 
with UA for 6 and 18hr and found that UA decreased monocyte ASC at both 
time points. UA increased DUSP10 at 6 hours but there was no difference at 
18 hours (figure 3.11B). 
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Figure 3.11 UA treatment reduces ASC and increases DUSP10 expression.  
Western blots of ASC and DUSP10. A: Human blood monocytes were pre-treated 
with or without UA (0.6mM) for 2hr and 15, 30 or 60min with LPS (100ng/ml). B: 
Human blood monocytes were treated for 6hr or 18hr with or without UA (0.6mM). β-
actin was used as a loading control. Results are representative of two to six 
independent experiments from individual volunteers. 
 
In this instance UA had a measurable effect in the absence of LPS stimulation. 
This implicated a reduction in ASC levels and concomitant increase in 
DUSP10 expression (figure 3.11) as the initial event that was suppressing the 
monocyte inflammatory cytokine response to LPS. The enhancement of IL-10 
production appears to be a result of UA dependent changes to NFκB 
signalling (figure 3.8). 
 
3.3.9 Adenosine receptors and purine recognition 
Adenosine has been shown to have differential effects on leukocyte function, 
such as mediating chemotaxis178, reducing inflammatory cytokine production 
and enhancing IL-10179,180, through the four adenosine receptors subtypes: A1, 
A2a, A2b and A3.  All four receptor subtypes are present on monocytes181. 
Adenosine is the main physiological agonist of adenosine receptors and 
caffeine is an environmental non-selective antagonist182. UA shares the 
common core purine structure with adenosine and caffeine (figure 3.12)183. 
Therefore, UA could be signalling through an adenosine receptor to enhance 
LPS-induced IL-10 production. 
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Figure 3.12 Chemical structures of uric acid, adenosine and caffeine 
highlighting their core purine structure. 
 
 
3.3.10 The role of adenosine receptors in UA-enhanced monocyte IL-10 
production 
Considering the structural similarity between UA, adenosine and caffeine I 
tested the hypothesis that UA was enhancing LPS-induced IL-10 by signalling 
through one of the four adenosine receptors.  
I pre-treated monocytes with UA and known adenosine receptor antagonists 
to block the four receptors individually: SLV320 (A1), ZM241385 (A2a), 
PSB1115 (A2b) and VUF5574 (A3). I then stimulated with LPS and measured 
monocyte cytokine production. 
The A1, A2b and A3 receptor antagonists had no effect on the increased IL-
10 production caused by UA in LPS-stimulated monocytes (figure 3.13A, C 
and D). The A2a antagonist had no effect on LPS alone treated monocytes 
but inhibited LPS-induced IL-10 production in UA treated monocytes in a 
concentration dependent manner (figure 3.13B).  
This suggested that UA could be signalling through the A2a receptor to 
enhance production of IL-10 by monocytes stimulated with LPS. 
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Figure 3.13 A2a receptor antagonist inhibits the IL-10 increase caused by UA.  
Human blood monocytes were pre-treated with or without UA (0.6mM) and 
adenosine receptor antagonists for 1hr then stimulated with LPS (100ng/ml) for 18hr. 
A: SLV320 (A1), B: ZM241385 (A2a), C: PSB1115 (A2b) and D: VUF5574 (A3) IL-10 
production was measured by ELISA. Results are mean with SEM of triplicate 
measurements and are representative of two independent experiments from 
individual volunteers. 
 
 
Adenosine can be released by monocytes in an autocrine-signalling loop that 
enhances LPS-induced IL-10 via adenosine A2a receptor signalling184. 
Therefore, I investigated whether adenosine was involved in the UA-mediated 
increase in LPS-induced IL-10. I treated monocytes with adenosine 
deaminase (ADA) and/or the A2a receptor antagonist followed by adenosine 
or UA and then measured monocyte IL-10 production after LPS stimulation.   
There was no effect of adenosine, UA or ADA on IL-10 production in the 
absence of LPS stimulation (figure 3.14A-B). Both ADA and the A2a 
antagonist treatment decreased the basal level of LPS-induced IL-10, 
confirming a role for endogenous adenosine in increasing monocyte IL-10 
production (figure 3.14 white bars). Adenosine potently enhanced LPS-
induced IL-10 and this enhancement was blocked by ADA, the A2a antagonist 
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and the two combined. However, adenosine still moderately increased LPS-
induced IL-10 in the presence of the A2a receptor antagonist (figure 3.14A, 
brown bars). UA increased LPS-induced IL-10 production over LPS alone and 
this increase was not inhibited by ADA, the A2a antagonist or the two 
combined (figure 3.14B, red bars).  
 
 
Figure 3.14 UA increases monocyte IL-10 independently of adenosine and 
A2a receptor signalling.  
A: Human blood monocytes were pre-treated with or without Ad (adenosine, 0.1mM) 
or B: UA (0.6mM), ADA (adenosine deaminase 3U/ml), A2a (A2a receptor antagonist, 
20µM) for 1hr then stimulated with LPS (100ng/ml) for 18hr. IL-10 production was 
measured by ELISA. **p<0.01, ***p<0.001, ****p<0.0001. One-way ANOVA with 
Bonferroni post-test. Results are mean with SEM of triplicate measurements and are 
representative of three independent experiments from individual volunteers. 
 
 
These results showed that both ADA and the A2a antagonist inhibited 
endogenous and exogenous adenosine from enhancing LPS-induced IL-10. 
However, ADA and the A2a antagonist were unable to prevent UA from 
enhancing monocyte IL-10 production. Thus, it appeared that UA was not 
enhancing LPS-induced IL-10 by increasing adenosine release from 
monocytes.  
Interestingly, adenosine increased LPS-induced IL-10 in the presence of the 
A2a antagonist suggesting an increased capacity for adenosine to signal via 
the A2b receptor when the A2a receptor was blocked185. 
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3.3.11 A2a and A2b receptor signalling and protein kinase A (PKA) 
The A2a and A2b adenosine receptors have the same downstream signalling 
pathway186. Consequently, blocking the A2a receptor could potentially shift 
UA signalling from the A2a to the A2b receptor.  
To test whether UA could be signalling through the A2b receptor I measured 
IL-10 release from monocytes treated with combinations of UA and the A2a 
and A2b receptor antagonists then stimulated with LPS. Blockade of both the 
A2a and A2b receptors individually and combined did not prevent UA from 
enhancing monocyte IL-10 production after LPS stimulation (figure 3.15A). 
Signalling through the A2a or A2b receptors activates protein kinase A (PKA); 
an intermediate kinase in the canonical cAMP-signalling pathway downstream 
of adenosine A2a and A2b receptors187. To see whether blocking PKA could 
prevent UA from augmenting LPS-induced IL-10 I treated monocytes with a 
specific PKA inhibitor (KT 5270) in combination with UA, then stimulated them 
with LPS. 
The PKA inhibitor reduced IL-10 production from LPS only treated monocytes 
but did not prevent UA from increasing LPS-induced IL-10 (figure 3.15B).  
Collectively these results showed that UA was increasing the production of IL-
10 from LPS-stimulated monocytes independently of both adenosine release 
and direct activation of the adenosine A2a and A2b receptors. 
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Figure 3.15 UA does not signal through the A2a or A2b receptor.  
A: Human blood monocytes were pre-treated with or without UA (0.6mM), A2a (A2a 
receptor antagonist, 20µM), A2b (A2b receptor antagonist, 100nM) for 1hr then 
stimulated with LPS (100ng/ml) for 18hr. B: Human blood monocytes pre-treated with 
or without UA (0.6mM) and KT 5720 (PKA inhibitor, 1µM) for 1hr then stimulated with 
LPS (100ng/ml) for 18hr. IL-10 production was measured by ELISA. **p<0.01, 
****p<0.0001. One-way ANOVA with Bonferroni post-test. Results are mean with 
SEM of triplicate measurements and are representative of two independent 
experiments from individual volunteers. 
 
3.3.12 Monocyte homotypic aggregation 
Studies of human monocytic U937 cells have shown that activation causes 
homotypic aggregation188,189.  
While investigating monocyte cytokine production I observed that LPS 
treatment caused the cells to aggregate together in small clusters and UA 
increased the size of LPS-induced clusters (figure 3.16C-D). UA alone did not 
induce monocyte aggregation (figure 3.16A-B). I also measured the size of 
each monocyte cluster using ImageJ software, normalising to LPS alone, and 
counted the number of clusters in each treatment. UA treatment increased 
average cluster size and there was a trend towards a decrease in the total 
number of clusters in LPS-stimulated monocytes (figure 3.16E-F). There was 
a reciprocal relationship between cluster size and the number of clusters 
suggesting that monocytes were migrating together to form the clusters.  
Adhesion and migration are important monocyte functions. This led me to 
investigate UA’s effect on monocyte aggregation, in parallel with the cytokine 
production studies detailed earlier, to see if there was a common mechanism 
involved in both aggregation and cytokine production. 
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Figure 3.16 Monocyte aggregation is enhanced by UA.  
A-D: Human blood monocytes were pre-treated with or without UA (0.6mM) for 1hr 
then stimulated with LPS (100ng/ml) for 18hr. Results are representative of three 
independent experiments from individual volunteers. E: Average cluster size, relative 
to LPS alone. F: Cluster number. ****p<0.0001, student’s t-test. Results are mean 
with SEM of triplicate measurements and are representative of three independent 
experiments from individual volunteers. 
 
 
3.3.13 Monocyte aggregation and adenosine receptor activation 
Signalling via the adenosine receptors regulates cytokine production in 
activated monocytes180 but also alters chemokine receptor and adhesion 
molecule expression178. Therefore, I hypothesised that UA was signalling 
through adenosine receptors to enhance LPS-induced monocyte homotypic 
aggregation. 
To study adenosine receptor involvement in monocyte homotypic aggregation 
I compared the effect of UA and adenosine on LPS-induced monocyte 
aggregation and found that both UA and adenosine increased aggregation of 
LPS treated monocytes (figure 3.17A-C). I then used adenosine receptor 
antagonists to block the four adenosine receptors individually. The A1, A2b 
and A3 receptor antagonists had no effect, while the A2a receptor antagonist 
potently inhibited LPS-induced monocyte aggregation (figure 3.17, left 
column). The A2a receptor antagonist also inhibited monocyte aggregation in 
the presence of UA and adenosine (figure 3.17G-I). 
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Figure 3.17 Monocyte aggregation is inhibited by the A2a receptor antagonist.  
A-O: Human blood monocytes were pre-treated with or without UA (0.6mM) or 
adenosine (0.1mM) and adenosine receptor antagonists for 1hr then stimulated with 
LPS (100ng/ml) for 18hr. Adenosine receptor antagonist concentrations were: A1 
(5nM), A2a (20µM), A2b (100nM) and A3 (40nM). Results are representative of two 
independent experiments from individual volunteers. 
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Figure 3.18A shows again that UA and adenosine both increased the size of 
LPS-induced monocyte clusters and demonstrated that UA increased cluster 
size when combined with the different receptor antagonists. However, there 
was no clear relationship between adenosine receptor antagonists and the 
number of clusters (figure 3.18B).  
 
 
Figure 3.18 Monocyte aggregation, but not cluster formation, is inhibited by 
the A2a receptor antagonist.  
Monocytes were treated as in figure 3.17. A: Monocyte cluster size relative to LPS 
alone. B: Average number of clusters in each field of view. *p<0.05, ***p<0.001, 
****p<0.0001, Two-way ANOVA with Bonferroni post-test. Results are mean with 
SEM of A: total clusters per field of view and are representative of three independent 
experiments from individual volunteers and B: total number of clusters and are 
combined from three independent experiments from individual volunteers. 
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As discussed earlier adenosine can be released from activated monocytes to 
feed back in an autocrine manner184 and treatment with the A2a antagonist 
alone reduced LPS-induced monocyte aggregation (figure 3.17A vs. G). This 
suggested a role for endogenous monocyte derived adenosine in mediating 
LPS-induced aggregation and UA may simply be increasing adenosine 
release and subsequently increasing aggregation.  
To investigate the relationship between of UA and adenosine in mediating 
monocyte homotypic aggregation I treated monocytes with adenosine 
deaminase (ADA) to remove adenosine from the culture system. Monocytes 
pre-treated with ADA, then stimulated with LPS formed smaller clusters than 
when treated with LPS alone (figure 3.19A vs. D). Combined treatment with 
ADA and the A2a antagonist also resulted in decreased LPS-induced 
monocyte aggregation (figure 3.19A vs. J). UA enhanced LPS-induced 
aggregation in the presence of ADA (figure 3.19D vs. E), the A2a antagonist 
(figure 3.19G vs. H) and the two combined (figure 3.19J vs. K). Adenosine did 
not enhance LPS-induced monocyte aggregation when ADA, the A2a 
antagonist or the two combined were present (figure 3.19G, I, J and L). 
Measuring cluster size shows graphically that UA enhanced LPS-induced 
monocyte aggregation regardless of ADA or A2a antagonist treatment. 
Adenosine also increased cluster size but this increase was removed by 
treatment with either ADA or the A2a antagonist (figure 3.20A). Again there 
was no clear pattern present when comparing the number of clusters in each 
treatment group (figure 3.20B).  
These results showed that the release of endogenous adenosine from 
monocytes was important for potentiating aggregation during LPS stimulation. 
As with the LPS-induced monocyte cytokine production UA was not 
enhancing adenosine release or signalling directly through the A2a receptor to 
increase monocyte aggregation. 
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Figure 3.19 UA enhances LPS-induced aggregation independently of 
adenosine signalling.  
A-L: Human blood monocytes were pre-treated with or without UA (0.6mM) or 
adenosine (0.1mM) plus ADA (3U/ml) and/or A2a antagonist (10µM) for 1hr then 
stimulated with LPS (100ng/ml) for 18hr. ADA=Adenosine deaminase. Results are 
representative of three independent experiments from individual volunteers. 
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Figure 3.20 UA enhances LPS-induced aggregation independently of 
adenosine signalling.  
Monocytes were treated as in figure 3.19. A: Monocyte cluster size relative to LPS 
alone. B: Average number of clusters in each field of view. ***p<0.001, ****p<0.0001, 
Two-way ANOVA with Bonferroni post-test. Results are mean with SEM of A: total 
clusters per field of view and are representative of three independent experiments 
from individual volunteers and B: total number of clusters and are combined from 
three independent experiments from individual volunteers. 
 
3.3.14 Monocyte adhesion molecule expression 
Monocytes use adhesion molecules to move from the circulation into the 
tissues. CD162 and CD62L promote rolling and tethering to the 
endothelium190,191. CD11b is involved in firm adhesion and CD31 in 
transmigration192. I hypothesised that UA was increasing the expression of 
these adhesion molecules in LPS activated monocytes and thereby increasing 
aggregation. 
To determine the effect of UA on the expression of monocyte adhesion 
molecules I measured CD62L, CD11b, CD31 and CD162 after treatment with 
combinations of UA, adenosine and LPS. UA and adenosine had no effect on 
adhesion molecule expression in untreated (figure 3.21A) or LPS treated 
monocytes (figure 3.21B). Therefore, it was unlikely that these adhesion 
molecules were contributing to the increased LPS-induced homotypic 
monocyte aggregation caused by UA. 
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Figure 3.21 Monocyte adhesion molecule expression is unchanged by UA or 
adenosine.  
A: Human blood monocytes were cultured in the absence (black lines) or presence of 
UA (0.6mM, brown lines) or adenosine (0.1mM, red lines) B: As in (A) with the 
addition of LPS (100ng/ml). Surface marker expression was analysed at 1, 2, 4 and 
18hr by flow cytometry. Results are mean with SEM of triplicate measurements and 
are representative of two independent experiments from individual volunteers. 
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3.3.15 Monocyte chemokine production 
Activated monocytes produce chemokines that recruit immune cells to areas 
of inflammation. It has been demonstrated that UA can directly stimulate non-
immune cells to produce CCL272 and the Harper group has shown that 
hyperuricaemia correlates with increased CCL2 levels and monocyte numbers 
in the blood128. CCL2, along with CCL3, CCL4 and CCL7 are monocyte 
chemoattractants, which are also produced by activated monocytes193,194. 
Therefore, I investigated UA’s effect on monocyte chemokine production to 
see if it was linked to LPS-induced homotypic aggregation. 
I measured monocyte release of CCL2, CCL3, CCL4 and CCL7 after 
exposure to different combinations of UA, adenosine and LPS. Unstimulated 
monocyte chemokine production was negligible and was not affected by either 
UA or adenosine treatment alone. In LPS treated monocytes there was a 
trend toward UA decreasing CCL3, CCL4 and CCL7 compared to LPS alone, 
which was not statistically significant. The addition of adenosine to LPS-
treated monocytes significantly decreased production of all four chemokines 
(figure 3.22). From these results it was evident that UA was not increasing 
LPS-induced monocyte homotypic aggregation by augmenting production of 
chemokines investigated in this study.  
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Figure 3.22 Monocyte chemokine production is not affected by UA.  
Human blood monocytes were pre-treated with or without UA (0.6mM) or adenosine 
(0.1mM) for 1hr then stimulated with LPS (100ng/ml) for up to 18hr. Chemokine 
production was assessed by multiplex cytokine bead array at 4hr (CCL2), 1hr (CCL3), 
2hr (CCL4) and 18hr (CCL7). *p<0.05, **p<0.01. Two-way ANOVA with Bonferroni 
post-test. Results are mean with SEM of triplicate measurements and are 
representative of two independent experiments from individual volunteers. 
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3.4 Summary 
The purpose of this chapter was to explore the effect of soluble UA, using an 
in vitro model of hyperuricaemia, on monocyte inflammatory responses to 
LPS and investigate the mechanisms through which soluble UA could be 
acting. To this end I have found that soluble UA initiated a silent suppressive 
switch in human blood monocytes that caused a functional shift in the 
presence of an immune stimulus. LPS stimulation combined with soluble UA 
treatment decreased pro-inflammatory cytokine release, enhanced IL-10 
production and increased monocyte homotypic aggregation, without inducing 
monocyte cell death. Analysis of monocyte adhesion molecule expression and 
chemokine production showed that UA was not enhancing LPS-induced 
monocyte homotypic aggregation via upregulation of the adhesion molecules 
CD62L, CD11b, CD31 and CD162 or production of the chemokines CCL2, 
CCL3, CCL4 and CCL7. Despite the structural similarity between UA and 
adenosine there was no evidence that soluble UA was signalling through 
adenosine receptors to increase IL-10 production or monocyte aggregation.  
Importantly, treatment with soluble UA alone decreased monocyte ASC 
expression and increased DUSP10. This may be the initial event that shapes 
the downstream changes to MAP kinase and NFκB signalling following 
stimulation with LPS and results in a more suppressive inflammatory cytokine 
profile and increased homotypic aggregation. 
 
The focus of Chapter 3 was on the direct effect of soluble UA on ex vivo 
human monocytes and the signalling pathways involved in soluble UA-
mediated suppression of the LPS response. The next chapter investigates 
how modulating serum UA levels in vivo alters systemic and monocytic 
responses to LPS and compares acute and chronic hyperuricaemia in this 
context.
  
 
Chapter 4: 
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4 Modulating serum uric acid in vivo 
4.1 Introduction  
Chapter 3 showed that treatment of human blood monocytes in vitro with 
soluble UA resulted in a suppressive cytokine response to LPS and 
decreased inflammatory signalling. Modelling hyperuricaemia in vivo provides 
a better understanding of the immunological effects of soluble UA on LPS-
induced inflammation in a more physiological context.  
Rodent models of acute and chronic hyperuricaemia have been used mainly 
to investigate the effectiveness of potential urate-lowering 
compounds139,140,195 and several studies indicate that in vivo hyperuricaemia 
has a regulatory role during inflammation117,157,165. Combined with my in vitro 
results from Chapter 3 these studies provided a solid rationale for 
investigating the immunosuppressive effects of soluble UA in vivo. 
Acute and chronic hyperuricaemia are associated with different pathologies. 
Acute hyperuricaemia during tumour lysis syndrome is a result of cell death 
induced by chemotherapy91. Chronic hyperuricaemia is commonly associated 
with metabolic syndrome and is the main risk factor for gout35. Modelling both 
acute and chronic hyperuricaemia will provide an insight into whether they 
have distinct effects during inflammation.  
Additionally, hyperuricaemia can be treated with different methods of urate-
lowering therapy (ULT) such as allopurinol and rasburicase, which provides 
an opportunity to investigate how current ULT may be influencing systemic 
and monocyte immune responses to inflammation. 
 
4.2  Aim 
The aim of this chapter was to investigate how manipulation of serum UA 
levels alters the in vivo inflammatory response to LPS.  
Chapter 4: Modulating Serum Uric Acid In Vivo 
 
68 
4.3 Results 
4.3.1 A mouse model of acute hyperuricaemia 
To raise serum UA in C57 mice I used a combinatorial approach, 
administering the uricase inhibitor oxonic acid (OA) followed by a bolus 
injection of soluble UA. Combined OA and UA treatment raised mouse serum 
UA levels 2-fold at 1hr post-UA administration (Figure 4.1). This ratio was 
comparable to the differences observed in human populations, where healthy 
individuals have serum UA levels of 240-360µM while hyperuricaemics often 
have levels of 500-600µM196.  
 
 
Figure 4.1 OA and UA induce acute hyperuricaemia in C57 mice. 
Serum UA levels of C57 mice (n=5) injected with oxonic acid i.p. (OA 300mg/kg) and 
soluble UA i.v. (12ug/kg) at the times indicated. Serum UA was measured using a 
fluorometric assay. ****p<0.0001, two-way ANOVA with Bonferroni post-test. Results 
are mean with SEM of triplicate measurements and are representative of two 
independent experiments.  
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Next I injected OA/UA treated mice with LPS i.v. and measured serum IL-10 
over a 24hr period. IL-10 peaked at 1hr post-LPS treatment and was 
enhanced by combined OA/UA treatment (figure 4.2). These data confirmed 
that hyperuricaemia increased systemic IL-10 production in vivo in response 
to LPS.   
 
 
Figure 4.2 IL-10 peaks in mouse serum 1 hour after LPS challenge.  
Serum IL-10 levels of C57 mice (n=4) pre-treated with or without oxonic acid (OA 
300mg/kg, 30min) and UA (12ug/kg, 1hr), then administered LPS i.v. (40ng/kg). 
Serum IL-10 was measured by ELISA. *p<0.05, two-way ANOVA with Bonferroni 
post-test. Results are mean with SEM of triplicate measurements and are 
representative of two independent experiments. 
 
 
4.3.2 Profiling the systemic cytokine response to LPS during acute 
hyperuricaemia 
In Chapter 3 I showed that in vitro treatment with soluble UA suppressed the 
proinflammatory cytokine response of monocytes stimulated with LPS. 
Therefore, I measured the levels of proinflammatory serum cytokines in naïve 
and hyperuricaemic mice at the peak of the IL-10 response, 1hr after LPS 
administration.   
Hyperuricaemia had no effect on serum cytokine levels in the absence of LPS 
stimulation. Serum IL-10 was increased in hyperuricaemic mice compared to 
controls following LPS administration (figure 4.3A). TNFα and IL-12p40 were 
reduced in hyperuricaemic mice after LPS administration (figure 4.3B and D). 
There was no difference in serum IL-6 levels in hyperuricaemic versus control 
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mice following LPS (figure 4.3E). Serum IL-1β levels were below the detection 
limit of the ELISA in all of the conditions investigated (figure 4.3C). These 
results indicated that hyperuricaemia was suppressing the inflammatory 
response to LPS in vivo. 
 
 
Figure 4.3 In vivo hyperuricaemia reduces inflammatory cytokines and 
increases IL-10 in response to LPS.  
Serum cytokine levels of C57 mice pre-treated with or without oxonic acid (OA 
300mg/kg, 30min) and UA (12ug/kg, 1hr), then administered LPS i.v. (40ng/kg, 1hr). 
A: Serum IL-10 (n=43), B: IL-12p40 (n=16), C: IL-1β (n=10), D: TNFα (n=18) and E: 
IL-6 (n=10) were measured by ELISA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
student’s t-test. Results are mean with SEM and are combined from at least two 
independent experiments. 
 
 
4.3.3 The in vivo cellular response to acute hyperuricaemia and LPS 
Next I investigated whether soluble UA caused the same signalling changes I 
had observed in human monocytes treated with soluble UA in vitro, namely 
decreased MAP kinase phosphorylation and ASC expression, and differential 
NFκB subunit nuclear translocation (appendices 7.2 and 7.1 and figure 3.9). 
Before I could look at signalling I needed to identify which cell types might be 
increasing IL-10 production in response to LPS during hyperuricaemia. To do 
this I isolated spleens from control and hyperuricaemic mice after LPS 
administration, cultured the whole splenocyte preparations with GolgiStop, an 
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intracellular protein transport inhibitor containing monensin, to prevent 
cytokine secretion then stained for cell surface markers and intracellular IL-10. 
There was a population of IL-10 positive cells in the spleen that were 
predominantly CD11b+ and Ly6C+, indicating that splenic monocytes were a 
source of IL-10 (figure 4.4A). By gating first on CD11b+/Ly6C+ cells (9% of 
whole splenocyte preparations) I saw that there was an increase in IL-10+ 
monocytes in hyperuricaemic versus control mice after LPS treatment (figure 
4.4B). These results indicated that the CD11b+/Ly6C+ positive monocytes in 
the spleen were producing IL-10 and were responding to acute 
hyperuricaemia by increasing IL-10 production following LPS challenge. I also 
investigated intracellular production of IL-12p40 and TNFα but could not 
detect either cytokine in splenic monocyte preparations. 
 
 
 
Figure 4.4 A population of splenic CD11b+/Ly6C+ monocytes produces IL-
10 upon LPS challenge and increases in frequency in hyperuricaemic mice.   
Splenic cells from C57 mice (n=5) pre-treated with or without oxonic acid (OA 
300mg/kg, 30min) and UA (12ug/kg, 1hr), then administered LPS i.v. (40ng/kg, 1hr). 
Cells were incubated in GolgiStop (1:1000, 4hr) then stained with cell surface and 
intracellular fluorescent antibodies and analysed by flow cytometry. A: Gating 
strategy to identify IL-10+ monocytes, B: Percent IL-10+ monocytes in each 
treatment group. Results are representative of two independent experiments. 
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Next I investigated the effects of hyperuricaemia and systemic LPS 
administration on splenic monocyte inflammatory signalling pathways. 
Following induction of acute hyperuricaemia and systemic inflammation with 
LPS I purified splenic monocytes using density gradient centrifugation 
followed by negative magnetic selection then isolated cytosolic and nuclear 
protein for western blotting.  
In vivo hyperuricaemia alone reduced splenic monocyte ASC expression 
(figure 4.5A). Following LPS stimulation DUSP10 expression was increased 
and phosphorylation of p38 and ERK1/2 MAP kinases was decreased in 
monocytes from hyperuricaemic mice compared to control (figure 4.5A). IκBα 
expression was also increased in the cytosol of splenic monocytes from 
hyperuricaemic mice challenged with LPS (figure 4.5A), which coincided with 
a decrease in NFκB p65 nuclear translocation (figure 4.5B). Densitometric 
analysis of the depicted western blots is presented in appendix 7.3A-G. 
These results showed that inflammatory MAP kinase and NFκB signalling 
within splenic monocytes was inhibited by acute hyperuricaemia during in vivo 
immune challenge with LPS. 
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Figure 4.5 Hyperuricaemia reduces ASC expression and MAP kinase 
phosphorylation in splenic monocytes and decreases NFκB p65 nuclear 
translocation.  
A: Cytosolic and B: nuclear protein from purified splenic monocytes isolated from 
C57 mice (n=5) pre-treated with or without oxonic acid (OA 300mg/kg, 30min) and 
UA (12ug/kg, 1hr), then administered LPS i.v. (40ng/kg, 1hr). Protein was analysed 
by western blotting. Results are representative of two independent experiments. 
 
 
ASC is a central component of the NLRP3 inflammasome, which is 
responsible for the cleavage and maturation of pro-IL-1β into active IL-1β115. 
Therefore, I investigated the expression levels of other inflammasome 
components in splenic monocytes from hyperuricaemic mice. 
Acute hyperuricaemia increased pro-caspase1 expression in both 
unstimulated and LPS-stimulated monocytes, but this appeared to be 
restricted to the larger isoform of pro-capase1 (upper band). (figure 4.6). 
There was also a decrease in active IL-1β in LPS treated monocytes from 
hyperuricaemic mice (figure 4.6). Densitometric analysis of the depicted 
western blots is presented in appendix 7.3H-L. 
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Figure 4.6 Hyperuricaemia increases pro-caspase1 expression and 
decreases active IL-1β  in splenic monocytes.  
Cytosolic protein from purified splenic monocytes isolated from C57 mice (n=5) pre-
treated with or without oxonic acid (OA 300mg/kg, 30min) and UA (12ug/kg, 1hr), 
then administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. 
 
 
4.3.4 Lowering serum UA in vivo 
The results from the previous sections showed that acute in vivo 
hyperuricaemia reduced systemic inflammatory cytokines in response to LPS, 
increased serum IL-10 and inhibited monocyte inflammatory signalling 
pathways. Next I tested the hypothesis that lowering serum UA would 
augment the systemic and cellular inflammatory response to LPS.  
Allopurinol  
To investigate the effect of lowering UA in vivo I treated mice with the ULT 
allopurinol for 3hr, which significantly reduced serum UA levels (figure 4.7A). I 
then administered LPS i.v. and measured the levels of serum cytokines. 
Allopurinol treatment alone had no effect on serum cytokine levels (figure 
4.7B-D). LPS-induced IL-10 production was decreased and IL-12p40 was 
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increased in allopurinol treated mice versus control (figure 4.7B-C). Allopurinol 
treatment had no effect on serum TNFα levels and there was a trend towards 
increased IL-6 in LPS treated mice (figure 4.7dD-E). 
 
 
 
 
 
Figure 4.7 Allopurinol treatment lowers serum UA and increases LPS-
induced systemic inflammation.  
A: Serum UA and B-E: cytokine levels of C57 mice pre-treated with or without 
allopurinol (30mg/kg, 3hr) then administered LPS i.v. (40ng/kg, 1hr). Serum UA was 
measured using a fluorometric assay. Serum cytokines were measured by ELISA.  
**p<0.01, ***p<0.001, student’s t-test. Results are mean with SEM and are  
combined from at least two independent experiments. A: n=10, B: n=20, C: n=15, D 
n=10, E: n=15. 
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I next investigated the effect of allopurinol and LPS treatment on protein 
expression in murine splenic monocytes by western blotting.  
Allopurinol had no effect on monocyte ASC or DUSP10 expression (figure 
4.8A). There was a decrease in LPS-induced p38 MAP kinase 
phosphorylation in allopurinol treated mice versus LPS alone but no changes 
to phosphorylated ERK1/2 (figure 4.8A). Allopurinol treatment resulted in a 
slight decrease in cytosolic IκBα expression (figure 4.8A, lower band) and a 
corresponding increase in NFκB p65 and p50 nuclear translocation in 
monocytes from LPS treated mice (figure 4.8B). Densitometric analysis of the 
depicted western blots is presented in appendix 7.4A-G. 
 
 
 
Figure 4.8 Allopurinol treatment reduces monocyte IκBα  expression and 
increases NFκB p65 nuclear translocation.  
A: Cytosolic and B: nuclear protein from purified splenic monocytes isolated from 
C57 mice (n=5) pre-treated with or without allopurinol (30mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. 
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Rasburicase 
I treated mice with rasburicase and found that, like allopurinol, a single 
rasburicase dose was sufficient to reduce serum UA after 3hr (figure 4.9A). I 
then measured cytokine levels in serum from LPS treated and control mice. 
There was no effect of rasburicase alone on serum cytokines (figure 4.9B-E). 
Although not statistically significant, rasburicase treatment produced a trend 
towards decreased IL-10 and increased IL-12p40 and IL-6 levels in LPS 
treated mice (figure 4.9B, C, E).  
 
 
 
 
Figure 4.9 Rasburicase treatment lowers serum UA but does not alter LPS-
induced systemic inflammation.  
A: Serum UA and B-E: cytokine levels of C57 mice pre-treated with or without 
rasburicase (0.8mg/kg, 3hr) then administered LPS i.v. (40ng/kg, 1hr). Serum UA 
was measured using a fluorometric assay. Serum cytokines were measured by 
ELISA. ***p<0.001, student’s t-test. Results are mean with SEM and are combined 
from at least two independent experiments. A: n=8, B: n=8, C: n=8, D n=8, E: n=8. 
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Next I examined whether splenic monocyte signalling pathways were being 
affected by rasburicase treatment. I purified splenic monocytes from control, 
rasburicase, LPS and rasburicase plus LPS treated mice to measure cytosolic 
and nuclear protein expression by western blotting. 
Rasburicase treatment alone increased monocyte ASC and DUSP10 
expression, while LPS in combination with rasburicase reduced ASC and 
DUSP10 expression compared to LPS alone (figure 4.10A). Rasburicase had 
no effect on MAP kinase phosphorylation or IκBα expression (figure 4.10A). 
Following densitometric analysis the nuclear fractions showed a relative 
increase in NFκB p65 or p50 subunit translocation after LPS and rasburicase 
treatment (figure 4.11B). Densitometric analysis of the depicted western blots 
is presented in appendix 7.5A-G. 
 
Figure 4.10 Rasburicase treatment alone increases monocyte ASC 
expression and NFκB nuclear translocation.  
A: Cytosolic and B: nuclear protein from purified splenic monocytes isolated from 
C57 mice (n=5) pre-treated with or without rasburicase (0.8mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Lanes have been 
cropped from a single blot for display purposes. 
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I also compared the effects of allopurinol and rasburicase treatment on the 
expression of NLRP3 inflammasome components in splenic monocytes from 
mice with or without LPS administration. Both allopurinol and rasburicase 
treatment alone decreased monocyte expression of pro-caspase1 and this 
decrease was still evident following LPS challenge. Rasburicase also 
decreased pro-IL-1β after LPS (figure 4.11). Densitometric analysis of the 
depicted western blots is presented in appendix 7.6A-E. 
 
 
 
 
 
Figure 4.11 ULT with rasburicase increases NLRP3 but decreases pro-
caspase1 and pro-IL-1β  expression in splenic monocytes.  
Cytosolic protein from purified splenic monocytes isolated from C57 mice (n=5) pre-
treated with or without allopurinol (30mg/kg, 3hr) or rasburicase (0.8mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. 
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Together these results showed that lowering serum UA with allopurinol but not 
rasburicase increased the systemic inflammatory cytokine response to LPS 
and decreased serum IL-10 levels. Allopurinol and rasburicase treatment also 
had differential effects on the inflammatory signalling pathways of splenic 
monocytes: allopurinol and rasburicase altered NFκB while only rasburicase 
altered ASC, NLRP3 and pro-IL-1β expression. 
 
4.3.5 A mouse model of chronic hyperuricaemia 
I had shown that acute changes to serum UA levels altered systemic cytokine 
responses and splenic monocyte inflammatory signalling in response to LPS. 
Next I wanted to investigate how chronic hyperuricaemia, which is closer to 
the human condition, affected systemic inflammation.  
The UrahPLT2/PLT2 (PLT2) mouse strain was identified during a mutagenesis 
screen and has a point mutation in the Urah gene that codes for 5-
hydroxyisourate (HIU) hydrolase90. Normally the endpoint of purine 
metabolism in mice is allantoin but the PLT2 strain has had its purine 
metabolic pathway disrupted at HIU hydrolase, the enzyme following uricase 
(figure 4.12). The effect of this mutation on the PLT2 strain’s serum UA level 
has not been reported. I hypothesised that the mutation of HIU hydrolase and 
resulting build up of HIU would produce an increase in serum UA, possibly as 
a result of product inhibition of uricase by HIU.  
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Figure 4.12 Mouse purine metabolic pathway from hypoxanthine to allantoin.  
HIU hydrolase has been knocked out in the PLT2 mouse strain. XOR = xanthine 
oxidoreductase, HIU = 5-hydroxyisourate, OHCU = 2-oxo-4-hydroxy-4-carboxy-5-
ureidoimidazoline. 
 
I measured the serum UA levels of PLT2 and C57 mice and found that PLT2 
mice were hyperuricaemic (figure 4.13A). The 2-fold increase in serum UA 
between C57 and PLT2 mice was comparable to the acute hyperuricaemia I 
had generated in C57 mice using administration of OA and UA (figure 4.1).  
Having confirmed that the PLT2 strain was indeed hyperuricaemic I 
investigated the effect of this chronic hyperuricaemia on serum cytokine levels 
using my LPS model of systemic inflammation.  
There was no difference in cytokine levels of naïve C57 and PLT2 mice. 
Following LPS administration PLT2 mice had higher levels of the serum 
cytokines IL-10, IL12-p40 and TNFα and there was a trend towards higher IL-
6 (figure 4.13B-E). This differed from the effects of acute hyperuricaemia, 
which increased serum IL-10 but decreased proinflammatory cytokines in 
response to LPS. 
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Figure 4.13 Serum UA and cytokine levels are higher in LPS treated PLT2 
mice compared with C57 mice.  
A: Serum UA and B-E: cytokine levels of C57 and PLT2 mice administered LPS i.v. 
(40ng/kg, 1hr). Serum UA was measured using a fluorometric assay. Serum 
cytokines were measured by ELISA. *p<0.05, **p<0.001, ****p<0.0001, student’s t-
test. Results are mean with SEM and are combined from at least two independent 
experiments. A: n=10, B: n=20, C: n=9, D n=18, E: n=13. 
 
 
I also compared the effect of chronic hyperuricaemia on inflammatory 
signalling molecules in splenic monocytes from the C57 and PLT2 mice. I 
isolated splenic monocytes from the spleens of naïve and LPS treated C57 
and PLT2 mice and prepared cytosolic and nuclear protein for western 
blotting. There were no clear differences in either monocyte ASC expression 
or MAP kinase phosphorylation between C57 and PLT2 mice (figure 4.14A). 
DUSP10 expression was higher and IκBα levels were the same in the PLT2 
mouse following LPS stimulation (figure 4.14A) and there was little difference 
in NFκB p65 and p50 subunit translocation into the nucleus of monocytes 
from PLT2 compared to C57 mice with or without in vivo LPS stimulation 
(figure 4.14B). Densitometric analysis of the depicted western blots is 
presented in appendix 7.6A-G. 
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Figure 4.14 Chronic hyperuricaemia in PLT2 mice does not affect monocyte 
inflammatory signalling molecules with or without LPS challenge.  
A: Cytosolic and B: nuclear protein from purified splenic monocytes isolated from 
C57 and PLT2 mice (n=5) administered LPS i.v. (40ng/kg, 1hr). Protein was 
analysed by western blotting. Strain: C = C57 and P = PLT2. Results are 
representative of two independent experiments. Lanes have been cropped from a 
single blot for display purposes. 
 
 
 
I then analysed NLRP3 inflammasome component expression in splenic 
monocytes from C57 and PLT2 mice treated with or without LPS. Naïve 
monocytes from PLT2 mice had lower expression of pro-caspase1, caspase1 
and IL-1β compared to C57 mice (figure 4.15). Monocytes from PLT2 mice 
had increased expression of NLRP3 in the absence of LPS stimulation but 
decreased NLRP3 (figure 4.15) following LPS stimulation, which coincided 
with an absence of pro-IL-1β expression. Densitometric analysis of the 
depicted western blots is presented in appendix 7.6H-L. 
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Figure 4.15 After LPS challenge PLT2 mouse monocytes have decreased 
NLRP3 and pro-IL-1β expression compared to C57.  
Cytosolic protein from purified splenic monocytes isolated from C57 and PLT2 mice 
(n=5) administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Strain: C = C57 and P = PLT2. Results are representative of two independent 
experiments. Lanes have been cropped from a single blot for display purposes. 
 
 
These results showed that the systemic cytokine and monocyte signalling 
responses to LPS stimulation in chronic hyperuricaemia in the PLT2 strain 
differed significantly from the acute hyperuricaemia induced in C57 mice. 
The PLT2 strain produced significantly more pro-inflammatory serum 
cytokines following LPS stimulation compared to C57 mice. Chronic 
hyperuricaemia had little effect on splenic monocyte inflammatory signalling 
with the PLT2 mice showing a small increase in MAP kinase pathway 
phosphorylation but not NFκB nuclear translocation. Following LPS 
stimulation NLRP3 expression and pro-IL-1β expression was decreased in 
PLT2 mice compared to C57. 
 
 
4.3.6 Lowering serum UA in chronic hyperuricaemia 
Next I wanted to see if lowering serum urate in the PLT2 mice could alter the 
inflammatory response to LPS as it had in the C57 mice.  
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Allopurinol 
I treated PLT2 mice with allopurinol for 3hr then challenged with LPS for 1hr 
and measured serum UA levels and LPS-induced serum cytokines. 
Interestingly, allopurinol had no effect on PLT2 mouse serum UA levels (figure 
4.16A). Allopurinol treatment also had no effect on serum cytokine levels with 
or without LPS administration (figure 4.16B-E). There was a trend towards 
decreased serum IL-10 in allopurinol and LPS treated PLT2 mice versus LPS 
alone (figure 4.16B).  
 
 
 
 
Figure 4.16 Allopurinol treatment has no effect on either serum UA or LPS-
induced serum cytokines in PLT2 mice.  
A: Serum UA and B-E: cytokine levels of PLT2 mice pre-treated with or without 
allopurinol (30mg/kg, 3hr) then administered LPS i.v. (40ng/kg, 1hr). Serum UA was 
measured using a fluorometric assay. Serum cytokines were measured by ELISA. 
Results are mean with SEM and are combined from at least two independent 
experiments. A: n=15, B: n=18, C: n=18, D n=15, E: n=8.  
 
I then investigated protein expression in purified splenic monocytes from 
PLT2 mice after in vivo allopurinol treatment and LPS challenge. Expression 
and phosphorylation of cytosolic monocyte inflammatory proteins was not 
affected by allopurinol treatment in PLT2 mice (figure 4.17A). There was a 
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decrease in ERK1/2 phosphorylation in allopurinol and LPS treated PLT2 
mice but this pattern was not consistent in a repeat experiment indicating that 
more work is needed to define the effect of allopurinol on ERK1/2 
phosphorylation in the PLT2 strain. Densitometric analysis showed that 
allopurinol treatment had no effect on p65 and p50 in unstimulated mice but 
decreased NFκB p50 subunit nuclear translocation with LPS treatment (figure 
4.17B). Densitometric analysis of the depicted western blots is presented in 
appendix 7.7A-G. 
 
 
Figure 4.17 Allopurinol treatment has no effect on ASC expression in splenic 
monocytes from PLT2 mice.  
A: Cytosolic and B: nuclear protein from purified splenic monocytes isolated from 
PLT2 mice (n=5) pre-treated with or without allopurinol (30mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Lanes have been 
cropped from a single blot for display purposes. 
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Allopurinol treatment increased NLRP3 protein expression in splenic 
monocytes from LPS treated PLT2 mice but did not affect the expression of 
any other NLRP3 inflammasome components (figure 4.18). Densitometric 
analysis of the depicted western blots is presented in appendix 7.7H-L. 
 
            
Figure 4.18 Allopurinol treatment increases NLRP3 expression in splenic 
monocytes from PLT2 mice.  
Cytosolic protein from purified splenic monocytes isolated from PLT2 mice (n=5) pre-
treated with or without allopurinol (30mg/kg, 3hr) then administered LPS i.v. (40ng/kg, 
1hr). Protein was analysed by western blotting. Results are representative of two 
independent experiments. Lanes have been cropped from a single blot for display 
purposes. 
 
 
 
 
Acute allopurinol treatment had no effect on PLT2 mouse serum UA levels. 
This is likely to be the reason there was no effect of allopurinol on either the 
systemic cytokine levels or inflammatory monocyte signalling molecules in 
response to LPS challenge.  
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Rasburicase 
After testing allopurinol in the PLT2 strain I wanted to see if rasburicase 
treatment would have a similar or different effect. I treated PLT2 mice with or 
without rasburicase then administered LPS i.v. to investigate the effect of 
rasburicase on serum UA levels and inflammatory cytokine production. 
Unlike allopurinol, rasburicase treatment reduced serum UA levels in PLT2 
mice (figure 4.19A). However, there were no differences in LPS-induced 
serum cytokines between untreated and rasburicase treated PLT2 mice 
(figure 4.19B-E). 
 
 
 
 
Figure 4.19 Rasburicase treatment lowers serum UA but has no effect on 
LPS-induced systemic inflammation in PLT2 mice.  
Serum cytokine levels of C57 mice pre-treated with or without rasburicase (0.8mg/kg, 
3hr) then administered LPS i.v. (40ng/kg, 1hr). Serum UA was measured using a 
fluorometric assay. Serum cytokines were measured by ELISA. *p<0.05, student’s t-
test. Results are mean with SEM and are combined from two independent 
experiments.  A: n=8, B: n=8, C: n=8, D n=8, E: n=8. 
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Next I investigated inflammatory protein signalling in splenic monocytes from 
rasburicase treated PLT2 mice. Rasburicase treatment decreased DUSP10 
expression compared to control PLT2 mice (figure 4.20A). After LPS 
treatment there was an increase in ERK1/2 phosphorylation in monocytes 
from rasburicase treated PLT2 mice (figure 4.20A). Rasburicase treatment 
increased NFκB p65 subunit nuclear translocation in splenic monocytes 
following LPS challenge (figure 4.20B). Densitometric analysis of the depicted 
western blots is presented in appendix 7.8A-G. 
 
 
 
 
Figure 4.20 Rasburicase treatment increases p-ERK1/2 and increases NFκB 
p65 subunit nuclear translocation in splenic monocytes from PLT2 mice.  
A: Cytosolic and B: nuclear protein from purified splenic monocytes isolated from 
PLT2 mice (n=5) pre-treated with or without rasburicase (0.8mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Lanes have been 
cropped from a single blot for display purposes. 
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I analysed the expression of NLRP3 inflammasome components in 
rasburicase treated PLT2 mice with and without LPS challenge. Monocyte 
expression of pro-caspase1 and pro-IL-1β were increased in rasburicase 
treated PLT2 mice administered LPS (figure 4.21). Densitometric analysis of 
the depicted western blots is presented in appendix 7.8H-L. 
 
           
Figure 4.21 Rasburicase treatment increases pro-caspase1 and pro-IL-1β  
expression in splenic monocytes from PLT2 mice.  
Cytosolic protein from purified splenic monocytes isolated from PLT2 mice (n=5) pre-
treated with or without rasburicase (0.8mg/kg, 3hr) then administered LPS i.v. 
(40ng/kg, 1hr). Protein was analysed by western blotting. Results are representative 
of two independent experiments. Lanes have been cropped from a single blot for 
display purposes. 
 
 
These results demonstrated that rasburicase was effective at reducing serum 
UA levels in PLT2 mice, but had little effect on the monocyte inflammatory 
signalling profile with increased ERK1/2 phosphorylation and NFκB p65 
nuclear translocation. Also, this reduction in serum UA did not translate into 
an increase in systemic inflammatory cytokines or a decrease in serum IL-10 
after LPS administration. 
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4.4 Summary 
In this chapter I explored how changes to systemic UA levels influence the 
acute inflammatory response to a non-lethal dose of LPS in vivo. My in vitro 
results from Chapter 3 provided an experimental platform that I used to 
investigate the systemic inflammatory cytokine response and inflammatory 
signalling in splenic monocytes following in vivo LPS challenge. I started by 
investigating the effect of acute hyperuricaemia and found that, like my in vitro 
human monocyte results, raising UA levels reduced the inflammatory cytokine 
response to LPS and increased IL-10. Splenic monocytes from LPS-
stimulated mice with acute hyperuricaemia had a decreased inflammatory 
signalling profile similar to human blood monocytes with in vitro 
hyperuricaemia.  
Allopurinol and rasburicase both effectively lowered serum UA levels in C57 
mice but only allopurinol treatment resulted in increased inflammatory serum 
cytokines and decreased IL-10 in response to LPS administration. Lowering 
serum UA with allopurinol or rasburicase had differential effects on monocyte 
inflammatory signalling pathways where both treatments increased 
inflammatory NFκB signalling but only rasburicase increased ASC expression. 
This indicates that the mechanism of urate lowering may be an important 
consideration in determining the immunological outcome.  
As a model of chronic hyperuricaemia I used the PLT2 mouse strain and 
compared the systemic inflammatory responses of PLT2 and C57 mice to 
LPS challenge. There was an increase in IL-10 and pro-inflammatory serum 
cytokines in the PLT2 strain with increased MAP kinase phosphorylation. 
However, NLRP3 and pro-IL-1β expression were reduced in the PLT2 strain. 
The discrepancy between the results observed with acute vs chronic 
hyperuricaemia could be a result of the genetic mutation in the PLT2 mouse 
or may represent differences between the immunological effects of short-term 
and long-term hyperuricaemia.  
Finally I treated the PLT2 mice with allopurinol or rasburicase and found that 
acute allopurinol treatment had no effect on serum UA levels in the PLT2 
strain. Allopurinol also had no effect on serum cytokines or monocyte 
signalling during LPS-induced systemic inflammation, demonstrating that in 
Chapter 4: Modulating Serum Uric Acid In Vivo 
 
92 
the PLT2 mouse, acute allopurinol treatment did not affect cytokine and 
monocyte responses to LPS in the absence of UA lowering. However, 
Rasburicase treatment, which lowered serum UA, did not alter serum 
cytokines but did increase the monocyte inflammatory signalling profile via 
increased ASC expression, decreased DUSP10 and increased NFκB p65 
nuclear translocation. Indicating again that the mechanism of urate lowering 
may be an important factor in determining the immunological effect of soluble 
UA. 
Taken together, these results confirmed that, like acute in vitro 
hyperuricaemia, acute in vivo hyperuricaemia suppressed inflammatory 
cytokines and monocyte inflammatory signalling. The effect of allopurinol and 
rasburicase on systemic and monocytic responses to LPS in C57 mice 
provided proof of concept to support the development of a clinical study to 
investigate urate-lowering therapy. Chapter 5 investigates how urate-lowering 
therapy modulates the response of human blood monocytes to immune 
stimuli. 
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5 Urate-lowering therapy study 
5.1 Introduction 
Urate-lowering therapy (ULT) is prescribed primarily for the treatment and 
prevention of gouty arthritis83. However, it is also used during chemotherapy 
of haematological cancers to combat tumour lysis syndrome, where extensive 
cell death causes an acute spike in serum UA that can result in acute kidney 
injury197. In the previous two chapters I used in vitro soluble UA treatment and 
in vivo models of hyperuricaemia in combination with ULT to investigate the 
role of soluble UA in modulating LPS-induced inflammation. The overarching 
results were that increases in soluble UA suppressed monocyte responses to 
LPS and enhanced IL-10 production and that elements of this immune 
suppression could be reversed with ULT.  
The next stage was to test whether the suppressive effects of soluble UA 
could be reversed by ULT in the treatment of patients with hyperuricaemia. 
There are three different mechanisms of urate lowering: xanthine 
oxidoreductase inhibition, recombinant uricase treatment and uricosurics. 
Allopurinol, a xanthine oxidoreductase inhibitor, is the first line ULT for 
hyperuricaemia associated with gout, which made it the best option for an 
initial proof of concept clinical study.  
A clinical study had been designed to examine the kinetics of allopurinol 
metabolism in patients with hyperuricaemia and gout and I expanded the 
scope of this study to examine the effect of ULT on the phenotype of blood 
monocytes and their inflammatory function.  
 
5.2 Aim 
The aim of this chapter was to determine whether ULT increases the 
inflammatory cytokine and signalling responses of human blood monocytes. 
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5.3 Results 
5.3.1 Demographic data 
15 patients were sequentially recruited as described in the materials and 
methods (section 2.2.15). The study participants were 80% male and had a 
mean age of 62 (table 5.1) consistent with hyperuricaemia being more 
common in males and the ageing population35. Most patients were classed as 
overweight (BMI 25-29.9) or obese (BMI ≥30) with a mean BMI of 30.13kg/m2. 
Several patients also had metabolic syndrome related comorbidities such as 
diabetes, hypertension and ischemic heart disease, which is consistent with 
the BMI data and the well-established association between hyperuricaemia 
and metabolic syndrome (table 5.1). Anti-inflammatory medications are often 
prescribed as prophylaxis or treatment for the pain and inflammation 
associated with gout. Therefore, changes to patient anti-inflammatory 
medications were also recorded at baseline and day 28 (table 5.1). Patient 
comorbidities and medications could influence the phenotype and function of 
immune cells and should be considered when interpreting the results of this 
study. However, given the small sample size and preliminary nature of this 
study I was unable to exclude patients with comorbidities or those that used 
anti-inflammatory medications.  
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Table 5.1  Serum UA levels, demographic data, comorbidities and 
medication. 
 
Individual and mean values (SD) for patient serum UA (sUA) age and body mass 
index (BMI). Several patients also suffered from metabolic syndrome related 
disorders and were taking anti-inflammatory medication. Cytokine and protein 
analysis columns denote which treatment patient monocytes were stimulated with for 
cytokine and protein analysis.  *p<0.05 patient serum UA levels at day 0 vs day 1 
and ***p<0.001 day 0 vs day 28, paired samples t-test. Patient AUHG05 started 
allopurinol before the study began. 
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5.3.2 Patient serum UA levels 
All the patients were hyperuricaemic (serum UA ≥0.42mM) at the beginning of 
the study with a mean serum UA level of 0.54mM (table 5.1). ULT with 
allopurinol significantly reduced serum UA levels by day 1 with further 
significant reduction by day 28 (table 5.1). The majority of patients were still 
hyperuricaemic at day 28 and none had reached the target level of <0.36mM, 
which may be due to the low dose of allopurinol (50-100mg/day). 
 
 
 
Figure 5.1 ULT reduces patient serum UA levels.  
Patient serum UA levels measured on day 0, day 1 and day 28 of ULT. 
HUA=Hyperuricaemia. *p<0.05, **p<0.01, ***p<0.001, paired samples t-test. Graph 
displays median, upper and lower quartiles, maximum and minimum.  
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5.3.3 Blood monocyte percentages  
There are two main monocyte subsets in the blood, the CD14+ circulating 
monocytes and the CD14+/CD16+ patrolling monocytes, both of which are 
CD11b positive119. The Harper group has shown that hyperuricaemia 
positively correlates with increased serum CCL2, a major monocyte 
chemokine, and that serum CCL2 in turn positively correlates with CD14+ 
blood monocyte percentages128. To determine whether ULT altered the 
percentages of the two blood monocyte subsets I stained whole white blood 
cell (WBC) preparations with antibodies for CD14 and CD16 and analysed the 
populations by flow cytometry. Figure 5.2 is a representative flow plot showing 
the two blood monocyte populations (CD14+ and CD14+/CD16+) and the 
larger neutrophil population (CD16+).  
 
 
 
Figure 5.2 Representative flow plot of CD14 and CD16 stained white blood 
cells (WBC).  
Isolated WBC were stained with fluorescent antibodies for CD14 and CD16 then 
analysed by flow cytometry.  
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ULT had no significant effect on the overall percentages of blood monocytes 
or neutrophils (figure 5.3a-c). I also analysed the cell percentages from each 
patient versus the patient’s serum UA level at each time point. This analysis 
produced a positive correlation between serum UA and the percentage of 
CD14+ blood monocytes (figure 5.3d). There was a trend towards increased 
CD14+/CD16+ monocytes with increasing serum UA and there was no 
association between serum UA and neutrophils (figure 5.3e-f). 
 
 
 
Figure 5.3 Monocyte and neutrophil percentages before and after ULT.  
Patient WBC (n=8) were stained with fluorescent antibodies for CD14, CD16 and 
CD11b and cell percentages were analysed by flow cytometry. Percentage of A: 
CD14+ monocytes, B: CD14+/CD16+ monocytes and C: CD16+ neutrophils. Graphs 
display median, upper and lower quartiles, maximum and minimum. Correlation 
analysis of D: CD14+ monocytes, E: CD14+/CD16+ monocytes and F: CD16+ 
neutrophils from each patient at each time point compared to patient serum UA at 
each time point. **p<0.01, Pearson’s correlation coefficient.  
 
 
5.3.4 Serum chemokines and cytokines 
I measured the levels of chemokines and cytokines in patient serum before 
and after ULT. I found that ULT had no effect on serum CCL2 levels (figure 
5.4a) and there was no association when serum CCL2 from each patient at 
each time point was analysed alongside serum UA (figure 5.4b). This 
indicated that serum UA levels and blood monocyte percentages may not be 
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so tightly linked to CCL2 as we had first supposed. I also measured IL-8, 
CCL4, CCL5, CCL7, IL-10, IL-12p40, TNFα, IL-6, IL-1β and IL-1Ra. There 
was a negative correlation between serum IL-10 and IL-8 compared to serum 
UA levels but ULT had no effect on the other serum cytokines or chemokines 
measured (appendices 7.10 and 7.11).  
 
 
 
Figure 5.4 There is no relationship between ULT or serum UA levels and 
serum CCL2.  
Patient CCL2 levels (n=15) were measured in patient serum by multiplex bead array. 
A: Serum CCL2 levels grouped by treatment day. Graph displays median, upper and 
lower quartiles, maximum and minimum. B: Serum CCL2 levels compared to patient 
serum UA at each time point. 
 
 
5.3.5 Adhesion molecule expression 
CD11b is highly expressed on circulating monocytes and is an important 
adhesion molecule involved in monocyte diapedesis through the blood vessel 
endothelium198. We have shown previously that monocytes from patients with 
hyperuricaemia and gout express more CD11b than monocytes from healthy 
controls128. Therefore, I analysed the mean fluorescent intensity (MFI) of 
CD11b expression of the two monocyte subsets and neutrophils from each 
patient by flow cytometry to determine whether ULT reduced CD11b 
expression. 
Figure 5.5a-c displays representative histograms of the downward shift in 
CD11b expression in monocytes and neutrophils at this time point. Analysis of 
the combined results showed that there was a trend towards decreased 
CD11b expression in CD14+ monocytes following ULT (figure 5.5d).  CD11b 
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expression on CD14+/CD16+ monocytes and CD16+ neutrophils at day 28 of 
ULT was significantly lower compared to day 0 (figure 5.5e-f). There was a 
positive correlation between monocyte CD11b expression and serum UA 
levels in all three cells subsets (figure 5.5g-i). These results indicated that the 
increased monocyte CD11b expression, associated with increased serum UA, 
levels could be reversed by ULT. 
 
 
Figure 5.5 Monocyte and neutrophil CD11b expression decreases with ULT.  
Patient WBC (n=8) were stained with fluorescent antibodies for CD14, CD16 and 
CD11b, and mean fluorescent intensity (MFI) was analysed by flow cytometry. 
Representative histograms of CD11b expression on A: CD14+ monocytes, B: 
CD14+/CD16+ monocytes and C: CD16+ neutrophils. CD11b expression of D: 
CD14+ monocytes, E: CD14+/CD16+ monocytes and F: CD16+ neutrophils. 
Correlation analysis of CD11b expression in G: CD14+ monocytes, H: CD14+/CD16+ 
monocytes and I: CD16+ neutrophils from each patient at each time point compared 
to patient serum UA at each time point. *p<0.05, **p<0.01, D-F: paired samples t-test, 
graphs display median, upper and lower quartiles, maximum and minimum. G-I: 
**p<0.01, Pearson’s correlation coefficient. 
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Next I investigated the effect of ULT on the expression of adhesion molecules 
on CD14+ monocytes after LPS stimulation. I used flow cytometry to measure 
the MFI of CD11b and ICAM1 on isolated blood monocytes following 18hr 
culture with or without LPS stimulation.  
Figure 5.6a and b are representative histograms of CD11b and ICAM1 
expression respectively displaying the reduced adhesion molecule expression 
on LPS-treated monocytes at day 1 and a further reduction at day 28. 
Analysis of the combined results from each patient at each time point showed 
a strong trend towards decreased CD11b and ICAM1 expression following 
ULT in unstimulated monocytes (figure 5.6c-d, Unstimulated). Expression of 
CD11b and ICAM1 was significantly lower in LPS treated monocytes after 28 
days of ULT (figure 5.6c-d, LPS).  
 
 
Figure 5.6 ULT reduces expression of monocyte adhesion molecules.  
Patient blood monocytes (n=9) were isolated and cultured for 18hr with or without 
LPS stimulation (100ng/ml), stained with fluorescent antibodies. A and C: CD11b and 
B and D: ICAM1 mean fluorescent intensity (MFI) was analysed by flow cytometry. 
*p<0.05, paired samples t-test. C-D: Graphs display median, upper and lower 
quartiles, maximum and minimum. 
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5.3.6 Monocyte cytokine production following ULT 
I demonstrated in Chapter 4 that murine ULT enhanced serum pro-
inflammatory cytokines and reduced IL-10 following in vivo LPS challenge. 
Therefore, I wanted to determine whether lowering serum UA in a clinical 
context resulted in an increase in pro-inflammatory cytokine production from 
human blood monocytes. To do this I cultured blood monocytes purified 
before and after ULT with or without LPS or MSU for 18hr and measured the 
production of multiple cytokines (IL-10, IL12p40, TNFα, IL-6, IL-1β and IL-
1Ra) in the culture supernatants.  
ULT had no effect on background monocyte IL-10 production (figure 5.7a, 
Unstimulated). 28 days of ULT significantly reduced monocyte IL-10 
production in response to LPS (figure 5.7a, LPS). As expected MSU did not 
stimulate monocytes to produce IL-10 above background levels (figure 5.7a, 
MSU). ULT did not alter IL12p40 production in unstimulated or stimulated 
monocytes (figure 5.7b).  
 
Figure 5.7 ULT reduces LPS-induced monocyte IL-10 production.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. A: IL-10 and B: IL-
12p40 in cell culture supernatants were analysed by ELISA or multiplex bead array. 
*p<0.05, paired samples t-test. Graphs display median, upper and lower quartiles, 
maximum and minimum. 
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I also analysed monocyte cytokine production in relation to each patient’s 
serum UA levels at each time point. There were no clear associations 
between IL-10 or IL-12p40 production and serum UA levels in unstimulated or 
stimulated monocytes (figure 5.8). 
 
 
 
Figure 5.8 Correlation analysis of monocyte IL-10 and IL12p40 production 
versus serum UA levels.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. Data is from each 
patient at each time point compared to patient serum UA at each time point. A-C: IL-
10 and D-F: IL-12p40 in cell culture supernatants were analysed by ELISA or 
multiplex bead array. 
 
 
 
ULT did not affect monocyte production of TNFα or IL-6 regardless of ex vivo 
stimulation (figure 5.9).  
However, when TNFα and IL-6 production was analysed in relation to serum 
UA levels there was a significant negative correlation between serum UA and 
both TNFα and IL-6 from MSU-stimulated monocytes (figure 5.10c and f). 
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Figure 5.9 ULT does not affect monocyte TNFα  or IL-6 production.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. A: TNFα and B: IL-6 
in cell culture supernatants were analysed by ELISA or multiplex bead array. Graphs 
display median, upper and lower quartiles, maximum and minimum. 
 
 
Figure 5.10 Serum UA negatively correlates with MSU-induced monocyte 
TNFα  and IL-6 production.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. Data is from each 
patient at each time point compared to patient serum UA at each time point. A-C: 
TNFα and D-F: IL-6 in cell culture supernatants were analysed by ELISA or multiplex 
bead array. *p<0.05, Pearson’s correlation coefficient. 
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I demonstrated in Chapter 3 that in vitro UA treatment decreased IL-β 
production in LPS-stimulated monocytes. IL-1 receptor antagonist (IL-1Ra) is 
produced as a negative feedback signal to inhibit IL-1β signalling199. 
Therefore, I measured the effect of ULT on both IL-1β and IL-1Ra in 
monocyte culture supernatants.  
ULT had no effect on either unstimulated or LPS-induced monocyte IL-1β 
production but MSU-stimulated monocytes produced less IL-1β after 28 days 
of ULT compared to day 0 (figure 5.11a). ULT did not affect IL1-Ra production 
in either unstimulated or stimulated monocytes (figure 5.11b).  
 
 
 
Figure 5.11 MSU-induced monocyte IL-1β  production is reduced following 
ULT.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. A: IL-1β and B: IL-
1Ra in cell culture supernatants were analysed by ELISA or multiplex bead array. 
*p<0.05, paired samples t-test. Graphs display median, upper and lower quartiles, 
maximum and minimum.  
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When monocyte IL-1β and IL1-Ra production was analysed in relation to 
serum UA levels there were no clear associations between serum UA levels 
and monocyte IL-1β or IL-1Ra production in either unstimulated or stimulated 
cells (figure 5.12). 
 
 
 
Figure 5.12 Correlation analysis of monocyte IL-1β  and IL-1Ra production 
compared to serum UA.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. Data is from each 
patient at each time point compared to patient serum UA at each time point. A-C: IL-
1β and D-F: IL-1Ra in cell culture supernatants were analysed by ELISA or multiplex 
bead array. 
 
ULT reduced the production of IL-10 from monocytes stimulated with LPS and 
there was a negative correlation between TNFα and IL-6 production after 
MSU stimulation and serum UA levels. Taken together these results indicated 
that ULT was removing an inhibitory effect of soluble UA to garner a more 
inflammatory monocyte response to both LPS and MSU. However, ULT 
reduced monocyte production of IL-1β following MSU stimulation, which 
suggests that UA may have differential effects on the mechanisms controlling 
IL-1β production and maturation compared to IL-10, TNFα and IL-6 following 
LPS vs. MSU stimulation. 
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5.3.7 Monocyte chemokine production following ULT 
Monocytes are an important source of chemokines during inflammation and 
chemokines released from the site of inflammation enhance recruitment of 
immune cells into the inflamed area. Therefore, I explored the effect of ULT 
on monocyte chemokine production. I measured the production of 
chemokines (IL-8, CCL2, CCL4, CCL5 and CCL7) in the culture supernatants 
of isolated monocytes stimulated with LPS or MSU for 18hr.  
There was no effect of ULT on monocyte IL-8 production in unstimulated or 
stimulated cells (figure 5.13a). There was a trend towards increased CCL2 
production in untreated and LPS treated monocytes after ULT and a 
significant increase in CCL2 production in MSU-stimulated monocytes after 28 
days of ULT compared to monocytes from day 0 (figure 5.13b). 
  
 
Figure 5.13 MSU-induced monocyte CCL2 production increases following 
ULT.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. A: IL-8 and B: CCL2 
in cell culture supernatants were analysed by ELISA or multiplex bead array. 
**p<0.01, paired samples t-test. Graphs display median, upper and lower quartiles, 
maximum and minimum. 
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When monocyte chemokine production was analysed in relation to serum UA 
levels there were no clear associations between either IL-8 or CCL2 
production and serum UA regardless of stimulation (figure 5.14). 
 
 
 
Figure 5.14 Correlation analysis of monocyte IL-8 and CCL2 production 
compared to serum UA.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. Data is from each 
patient at each time point compared to patient serum UA at each time point. A-C: IL-
8 and D-F: CCL2 in cell culture supernatants were analysed by ELISA or multiplex 
bead array. 
 
 
 
I also measured CCL4, CCL5 and CCL7 to investigate the broader effect of 
ULT on monocyte chemokine production following LPS or MSU stimulation. 
ULT did not affect production of CCL4, CCL5 and CCL7 in unstimulated 
monocytes (figure 5.15, Unstimulated). There was a trend towards increased 
production of all three chemokines in LPS-stimulated monocytes (figure 5.15, 
LPS). In MSU-stimulated monocytes there was a trend towards increased 
production of CCL5 after ULT and a significant increase in CCL7 after both 1 
and 28 days of ULT (figure 5.15b-c, MSU).  
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Figure 5.15 MSU-induced monocyte CCL7 production increases following 
ULT.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. A: CCL4, B: CCL5 
and C: CCL7 in cell culture supernatants were analysed by ELISA or multiplex bead 
array. *p<0.05, paired samples t-test. Graphs display median, upper and lower 
quartiles, maximum and minimum. 
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Correlation analysis of chemokine production relative to serum UA levels 
showed that CCL4, CCL5 and CCL7 from unstimulated monocytes trended 
down with increasing serum UA levels (figure 5.16a, d and g). Furthermore, 
there was a significant negative correlation between chemokine production 
and serum UA levels of CCL4 in LPS-stimulated monocytes and CCL5 in 
MSU-stimulated monocytes (figure 5.16b and f).  
Taken together, these results indicated that ULT was enhancing the 
production of multiple chemokines in LPS and MSU-stimulated monocytes 
and suggested that serum UA levels might have a stronger influence on CCL2 
(monocytes) over IL-8 (neutrophils) dependent recruitment. 
 
 
 
Figure 5.16 Correlation analysis of monocyte CCL4, CCL5 and CCL7 
production compared to serum UA.  
Patient blood monocytes were isolated and cultured for 18hr unstimulated (n=15) or 
with LPS (100ng/ml n=15) or MSU (0.5mg/ml n=7) stimulation. Data is from each 
patient at each time point compared to patient serum UA at each time point. A-C: 
CCL4, D-F: CCL5 and G-I: CCL7 in cell culture supernatants were analysed by 
ELISA or multiplex bead array. **p<0.01, Pearson’s correlation coefficient. 
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5.3.8 ULT and cytosolic monocyte MAP kinase signalling 
In Chapter 3 and 4 I showed that in vitro and in vivo hyperuricaemia 
suppressed inflammatory signalling in monocytes. Furthermore, the in vivo 
ULT studies suggested that some of these signalling changes could be 
reversed. Based on these results I hypothesised that ULT would increase 
monocyte inflammatory signalling in response to immune stimuli. In order to 
test this hypothesis I isolated cytosolic and nuclear protein from purified naive 
blood monocytes and from LPS or MSU-stimulated monocytes from patients 
at each stage of ULT and assessed the expression of inflammatory signalling 
molecules by western blotting.  
Figure 5.17 is a representative western blot and the densitometry of the 
combined data is shown in figure 5.18. ULT increased phosphorylation of both 
p38 and ERK1/2 MAP kinases in unstimulated and LPS or MSU-stimulated 
cells. Importantly, ULT also increased cytosolic ASC expression in stimulated 
and unstimulated monocytes confirming my in vitro and in vivo results 
indicating that soluble UA levels control monocyte ASC expression (figure 
5.17).  
 
I used densitometry to combine the relative band intensities from each patient. 
The intensity of protein bands for each treatment day was measured using 
ImageJ software. These were normalised to evaluate the fold change in 
protein expression at Day 1 and Day 28 relative to Day 0 then normalised 
again to the corresponding density of β-actin to control for differences in 
protein loading. The blots used for this analysis can be found in appendices 
7.12 and 7.13. 
Densitometric analysis of the combined western blots showed that ULT 
increased monocyte MAP kinase phosphorylation in unstimulated and LPS or 
MSU-stimulated cells (figure 5.18a-b). It also showed that 1 and 28 days of 
ULT increased monocyte ASC expression in unstimulated and stimulated 
monocytes (figure 5.18c). 
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Figure 5.17 ULT increases monocyte MAP kinase phosphorylation and ASC 
expression.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). Protein extracts were 
analysed by western blotting. 
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Figure 5.18 ULT increases monocyte MAP kinase phosphorylation and ASC 
expression.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). A: p-p38, B: p-ERK1/2 
and C: ASC western blot band intensity relative to β-actin and Day 0 were analysed 
using ImageJ. *p<0.05, t-test. Data are mean with SEM. 
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DUSP10 and DUSP1 are regulators of MAP kinase phosphorylation that have 
been implicated in the control of IL-10 production173,200.  
Figure 5.19 is a representative western blot of monocyte DUSP10 and 
DUSP1 and the phosphorylation status of DUSP1 and the densitometry of the 
combined data is shown in figure 5.20. ULT had no effect on the levels of 
DUSP10 or DUSP1 in unstimulated or stimulated monocytes (figure 5.19). 
However, ULT resulted in a large increase in DUSP1 phosphorylation in both 
LPS and MSU-stimulated monocytes (figure 5.19). 
 
 
 
Figure 5.19 ULT increases monocyte DUSP1 phosphorylation.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). Protein extracts were 
analysed by western blotting. 
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When combined using densitometry the DUSP10, DUSP1 and p-DUSP1 
western blots showed that ULT had no effect on the expression levels of 
DUSP10 and DUSP1 (figure 5.20a-b). However, after ULT there was an 
average 10-fold and 15-fold higher level of phosphorylated DUSP1 following 
LPS or MSU stimulation respectively (figure 5.20c). 
 
Figure 5.20 ULT increases monocyte DUSP1 phosphorylation.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). A: DUSP10, B: DUSP1 
and C: p-DUSP1 western blot band intensity relative to β-actin and Day 0 were 
analysed using ImageJ. Data are mean with SEM. 
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5.3.9 ULT and monocyte protein expression in the nucleus 
In Chapter 4 I showed that acute hyperuricaemia reduced the translocation of 
the NFκB p65 subunit into the nucleus of murine splenic monocytes following 
in vivo LPS stimulation. Additionally, ULT with allopurinol reversed this effect. 
Therefore, I wanted to establish whether ULT in patients with hyperuricaemia 
altered nuclear translocation of the p65 and p50 NFκB subunits in human 
blood monocytes.  
Figure 5.21 is a representative western blot of nuclear extracts from patient 
blood monocytes and the densitometry of the combined data is shown in 
figure 5.22. ULT increased p65 nuclear translocation in monocytes stimulated 
with LPS but not MSU (figure 5.21 and figure 5.22a). ULT also increased p50 
translocation in LPS stimulated monocytes (figure 5.22b).  
 
 
 
Figure 5.21 ULT increases monocyte NFκB p65 nuclear translocation and 
decreases nuclear p50.  
Nuclear protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=7) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=3). Protein extracts were 
analysed by western blotting. 
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Figure 5.22 ULT increases NFκB nuclear translocation in LPS-stimulated 
monocytes but decreases ASC and Bcl3 in MSU-stimulated monocytes. 
Nuclear protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=7) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=3). A: NFκB p65, B: NFκB 
p50, C: ASC and D: Bcl3 western blot band intensity relative to β-actin and Day 0 
were analysed using ImageJ. *p<0.05, t-test. Data are mean with SEM. 
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Bcl3 is an IκB protein that associates with the p50/p50 homodimer and has 
been reported to inhibit IL-10 transcription201. I measured nuclear Bcl3 
expression to investigate the mechanism behind the control of p50 subunit 
nuclear translocation by soluble UA.  
ASC has immunoregulatory effects in the nucleus by increasing mRNA 
stability in DC to support immune function176. Therefore, I wanted to 
investigate whether ULT altered nuclear expression of ASC in human blood 
monocytes.  
Densitometric analysis of the combined western blots showed that ULT 
increased ASC and Bcl3 at day 1 in unstimulated monocytes and at day 28 in 
LPS-stimulated monocytes. However, both ASC and Bcl3 were reduced 1 and 
28 days after ULT in MSU-stimulated monocytes (figure 5.22C and D). 
The increased NFκB p65 and decreased p50 translocation following ULT 
showed that the inflammatory potential of human blood monocytes was 
increased following ULT. 
 
5.3.10 Monocyte inflammasome signalling following ULT 
In Chapter 4 I showed that in vivo ULT increased monocyte ASC expression 
and decreased expression of other NLRP3 inflammasome components. To 
investigate this effect in the context of ULT I measured monocyte expression 
of NLRP3 inflammasome components by western blotting.  
Figure 5.23 is a representative western blot of monocyte NLRP3, caspase1 
and IL-1β before and after ULT and the densitometry of the combined data is 
shown in figure 5.24. Expression of NLRP3 increased in unstimulated 
monocytes and LPS or MSU-stimulated monocytes after 1 and 28 days of 
ULT (figure 5.23). ULT increased pro-caspase1 expression and this 
corresponded with a decrease in caspase1. Monocyte pro-IL-1β expression 
increased after ULT in LPS and MSU treated cells. There was very little IL-1β 
expression in monocytes following ULT (figure 5.23a) and figure 5.23b shows 
that ULT decreased IL-1β expression with or without MSU stimulation. 
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Figure 5.23 ULT increases monocyte NLRP3 inflammasome components.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). Protein extracts were 
analysed by western blotting. 
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When the NLRP3 inflammasome western blots were normalised and 
combined using densitometry it shows that ULT resulted in a 3 to 5-fold 
increase in NLRP3 and a 2 to 4-fold increase in pro-caspase1 expression in 
unstimulated and stimulated monocytes (figure 5.24a-b). Caspase1 
expression had decreased at day 1 and decreased further by day 28 of ULT in 
unstimulated and stimulated monocytes (figure5.24c). Pro-IL-1β expression 
increased in LPS and MSU-stimulated monocytes following ULT (figure 5.24d). 
Contrary to the IL-β expression in figure 5.23b, combined results showed that 
there was an overall increase in IL-1β expression following ULT in 
unstimulated monocytes but no difference in IL-1β expression after LPS or 
MSU stimulation (figure 5.24e). 
Overall ULT resulted in increased expression of NLRP3, pro-caspase1 and 
ASC, the three major subunits of the NLRP3 inflammasome and further 
confirms the inflammatory priming of human blood monocytes by ULT.  
Chapter 5: Urate-Lowering Therapy Study 
 
121 
 
Figure 5.24 ULT increases monocyte NLRP3 inflammasome components.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). A: NLRP3, B: pro-
Caspase1, C: Caspase1, D: Pro-IL-1β and E: IL-1β western blot band intensity 
relative to β-actin and Day 0 were analysed using ImageJ. *p<0.05, t-test. Data are 
mean with SEM. 
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5.4 Summary 
In this chapter I have presented results from a clinical study investigating how 
ULT, in patients with hyperuricaemia, alters monocyte inflammatory function. 
Allopurinol treatment significantly lowered serum UA levels over the course of 
the study. Serum UA levels positively correlated with the percentage of 
monocytes in the blood and with monocyte CD11b expression, confirming the 
Harper group’s previous findings comparing monocytes from normouricaemic 
to hyperuricaemic individuals128. I also extended this analysis, demonstrating 
that ULT reduced monocyte percentages and CD11b expression, thereby 
reinforcing the role of serum UA in the control of monocyte recruitment into 
the circulation and tissues.  
Monocytes produced less IL-10 in response to LPS after ULT and there was a 
negative correlation between TNFα and IL-6 production and serum UA levels 
after MSU stimulation. Monocytes also produced more chemokines, such as 
CCL2, CCL5 and CCL7, following ULT and immune stimulation. These data 
indicated that blood monocytes were becoming more inflammatory as serum 
UA levels decreased. 
The increased monocyte inflammatory profile was supported by western blot 
analysis, which showed that ULT caused an increase in MAP kinase 
phosphorylation and NFκB p65 and p50 nuclear translocation. ULT also 
increased monocyte ASC, NLRP3 and pro-caspase1 expression, the three 
central components of the NLRP3 inflammasome.  
The study was designed primarily to measure the kinetics of allopurinol 
metabolism in hyperuricaemic patients with gout over 28 days, using a 
constant allopurinol dose of 50 or 100mg/day depending on patient creatinine 
clearance. The usual practice of titrating the dose upwards83 to achieve target 
serum UA levels was not instigated until after the end of the study. Therefore, 
the main limitation of this study was the low starting dose of allopurinol and as 
such, the effect of reaching the target UA level of <0.36mM could not be 
evaluated. Other limitations include the different comorbidities of each patient, 
which could have unpredictable effects on monocyte function, and 
medications the patients were taking. Anti-inflammatory medications could 
influence the behaviour of immune cells and alter the systemic immune 
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environment but are a normal part of regular treatment and care of gouty 
arthritis. Additionally, there were some strong trends in the data that may 
prove to be biologically significant if measured in a larger patient group. 
 
The results of this chapter confirmed the suppressive effects of soluble UA by 
demonstrating that lowering of serum UA, in a clinical setting, increases the 
inflammatory potential of human blood monocytes. This study indicates that 
the suppression of monocyte inflammatory potential induced by 
hyperuricaemia can be reversed with pharmacological reduction of serum UA 
levels.
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6 Discussion and future directions 
6.1 Overview 
Hyperuricaemia is directly associated with metabolic syndrome, an umbrella 
term encompassing diseases that result from perturbations in energy 
metabolism. These conditions include obesity, type 2 diabetes, hypertension, 
ischemic heart disease and gout and are commonly associated with low-
grade chronic inflammation2.  
The widely reported associations between hyperuricaemia and chronic 
inflammation have meant that hyperuricaemia is commonly seen as a 
potential inflammatory driver. However, results from a previous observational 
study conducted in the Harper group (figure 3.1, unpublished data) provided 
evidence contrary to this hypothesis. Comparing the ex vivo responses of 
innate immune cells from healthy controls versus people with hyperuricaemia, 
the study found a negative correlation between LPS-induced monocyte pro-
inflammatory cytokine production and serum UA levels. This indicated that 
hyperuricaemia could in fact be moderating monocyte responses during 
chronic inflammation.  
The aim of my research was to expand on our understanding of the potential 
moderating effects of soluble UA on the pro-inflammatory response of blood 
monocytes to stimulation with LPS. Using a combination of in vitro, in vivo and 
clinical modulation of soluble UA my research has confirmed the ability of 
soluble UA to moderate blood monocyte pro-inflammatory cytokines alongside 
increased production of anti-inflammatory IL-10. This occurs in conjunction 
with decreased pro-inflammatory cytokine signalling and upregulation of anti-
inflammatory signalling pathways. 
 
Chapter 6: Discussion and Future Directions 
 
125 
6.2 Monocyte inflammatory signalling and cytokine production  
6.2.1 NFκB signalling 
In monocytes the NFκB p65/p50 heterodimer is activated by LPS stimulation 
to trigger pro-inflammatory cytokine transcription. p65/p50 is sequestered in 
the cytosol by IκBα and LPS stimulation triggers proteosomal degradation of 
IκBα releasing p65/p50 for nuclear translocation. IκBα is then gradually 
replenished via NFκB signalling in a negative feedback loop to shut down 
inflammation202.  
My results showed that in vitro and in vivo hyperuricaemia decreased p65 
nuclear translocation in LPS-stimulated monocytes and that there was a more 
rapid recovery of IκBα levels in the presence of hyperuricaemia. These 
results indicate that soluble UA could be enhancing IκBα through a post-
transcriptional mechanism to limit pro-inflammatory NFκB p65/p50 signalling 
and reduce pro-inflammatory cytokine production (figure 6.1). 
 
The NFκB p50/p50 homodimer is a transcription factor for the anti-
inflammatory cytokine IL-10 and is also inhibitory of p65/p50 signalling171. 
My data showed an increase in LPS-induced monocyte nuclear p50 in the 
presence of in vitro hyperuricaemia. This indicates that hyperuricaemia may 
be augmenting IL-10 and inhibiting pro-inflammatory p65/p50 signalling via 
increases in nuclear p50/p50. 
The possible mechanism behind increased nuclear translocation of the p50 
subunit is unclear. Bcl3 is a member of the IκB family of proteins that bind and 
inhibit NFκB transcription factors and has been implicated as an inhibitor of 
p50/p50-induced transcription of IL-10201. In the clinical study ULT coincided 
with an increase in nuclear Bcl3 expression, indicating that Bcl3 may be 
involved in the mechanism through which UA enhances LPS-induced IL-10 
production.   
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Figure 6.1 Potential mechanisms through which soluble UA suppresses 
monocyte inflammatory signalling.  
Soluble UA could decrease ASC expression via enhanced ubiquitination or 
deSUMOylation, thereby removing suppression of DUSP10. Increased nuclear ASC 
could enhance mRNA stability to support IκBα translation. It is unclear how UA might 
enhance nuclear trafficking of ASC and NFκB p50.  
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6.2.2 MAP kinase signalling 
LPS activates MAP kinase phosphorylation, a key event in the signal 
transduction pathway that leads to pro-inflammatory cytokine production.  
In my study, elevated UA levels (in vitro and in vivo) resulted in decreased 
p38 and ERK1/2 phosphorylation. I saw the reverse pattern in vivo with C57 
mice and in the ULT study. These findings demonstrate that hyperuricaemia 
reduces pro-inflammatory MAP kinase signalling in activated monocytes.  
A role for cytosolic ASC in MAP kinase regulation has been shown using 
knockdown of ASC with shRNA constructs where knockdown of ASC 
increased DUSP10 activity and dephosphorylation of ERK1/2175. My data 
indicated that in vitro and in vivo hyperuricaemia mediate suppression of MAP 
kinase phosphorylation in association with increased DUSP10 and decreased 
ASC expression. ULT in vivo and in the clinical study had the opposite effect, 
increasing ASC expression alongside MAP kinase phosphorylation. These 
results identify soluble UA as an endogenous regulator of monocyte ASC 
expression and suggest that the concentration of soluble UA can control the 
degree of LPS-induced MAP kinase phosphorylation via modulation of ASC 
expression (figure 6.1).   
 
Interestingly, ASC expression was reduced in monocytes after just 2hr of 
inducing in vitro or in vivo hyperuricaemia. This rapid reduction in cytosolic 
ASC suggests that soluble UA was reducing ASC expression through a post-
translational mechanism. One potential mechanism is proteosomal 
degradation, which involves the attachment of multiple ubiquitin molecules to 
cellular proteins to target them for removal by the proteosome203. There is 
evidence that ASC can be ubiquitinated following activation of autophagy204, 
providing a precedent for proteosomal degradation of ASC that could 
potentially be enhanced by increases in soluble UA (figure 6.1). 
 
Alongside ubiquitination there is SUMOylation, which involves covalent 
attachment of small ubiquitin-like modifiers (SUMO) to target proteins. 
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SUMOylation of proteins can result in many different functional outcomes 
including cytosol to nuclear trafficking and increased protein stability205,206. 
There is evidence that soluble UA can influence protein SUMOylation. One 
study shows that in mononuclear phagocytes overexpression of xanthine 
oxidoreductase (XOR) or treatment with soluble UA decreased SUMOylation 
of PPARγ207. However, the authors infer that increased activity of XOR rather 
than increased soluble UA reduces PPARγ SUMOylation despite showing that 
increased XOR and soluble UA treatment produce exactly the same result. It 
is therefore possible that this study demonstrates a precedent for increased 
soluble UA reducing protein SUMOylation. Therefore, hyperuricaemia could 
be causing ASC deSUMOylation and destabilisation, which may be driving the 
reduction in ASC observed in my research (figure 6.1).  
 
There is evidence that ASC has an important role in the nucleus supporting 
mRNA stabilisation of DOCK2 in both myeloid cells and lymphocytes. This 
was shown by a decrease in DOCK2 mRNA transcript levels, mRNA half-life 
and protein expression in ASC deficient cells176. My clinical study showed that 
ULT resulted in increased cytosolic and decreased nuclear ASC in human 
monocytes indicating soluble UA may increase nuclear trafficking of ASC. 
Increasing nuclear translocation of ASC could support mRNA stability of IκBα 
transcripts (figure 6.1), which would in turn reduce pro-inflammatory NFκB 
p65/p50 signalling after LPS stimulation. Nuclear translocation of ASC could 
also be a mechanism through which DUSP10 is released from inhibition by 
ASC in the cytosol. Whether ASC nuclear trafficking is regulated by 
SUMOylation is unknown. 
 
6.2.3 NLRP3 inflammasome signalling 
The NLRP3 inflammasome is a multiprotein complex comprised of NLRP3, 
ASC and pro-caspase1 that cleaves pro-IL-1β into the active form. ASC is a 
major component of the NLRP3 inflammasome and in vitro hyperuricaemia 
reduced both ASC expression and LPS-induced IL-1β.  
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At the same time, induction of acute hyperuricaemia in vivo increased pro-
caspase1 and pro-IL-1β expression in splenic monocytes and this pattern was 
reversed in C57 mice treated with allopurinol or rasburicase. However, ULT in 
the clinical study increased NLRP3, pro-caspase1 and pro-IL-1β expression in 
human blood monocytes. The reason for this differential expression pattern is 
unclear and may simply be a result of inherent differences in mouse and 
human immunology. However, in vivo ULT with rasburicase in the PLT2 strain 
also resulted in increased pro-caspase1 and pro-IL-1β expression. In this 
instance ULT produced the same functional changes during chronic 
hyperuricaemia in mice as it had in humans. Therefore, there is some 
commonality in NLRP3 inflammasome expression in response to ULT and the 
common factor may have been the presence of chronic hyperuricaemia. 
 
In the clinical study ULT increased NLRP3 inflammasome component 
expression, suggesting that the NLRP3 inflammasome would be more 
reactive in monocytes from a lower serum UA environment. MSU-induced 
pro-IL-1β protein expression was increased after ULT but MSU-induced IL-1β 
production was decreased. This indicates that inflammasome component 
expression (as measured by western blotting) does not always lead to 
increased cleavage and active IL-1β secretion (as measured by IL-1β ELISA).  
 
6.3 Monocyte adhesion molecule expression and CCL2 
CD11b is an adhesion molecule involved in the tethering of monocytes to the 
vascular endothelium at sites of inflammation208; ICAM1 is a ligand for CD11b 
and is important for monocyte-monocyte interactions and cell-cell adhesion 
between monocytes and other immune cells209; CCL2 is a major monocyte 
chemokine that can recruit monocytes from the bone marrow via the CCL2-
CCR2 chemokine-receptor axis118.  
We have already reported that hyperuricaemic individuals have more CD14+ 
monocytes in the circulation versus normouricaemic controls, that the 
monocytes from hyperuricaemics have increased CD11b expression and that 
these changes are associated with increased serum CCL2128. Another study 
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involving hyperuricaemic children also reports increased CCL2 levels in 
hyperuricaemics versus healthy controls210. Additionally, soluble UA has been 
shown to induce production of CCL2 in vascular smooth muscle cells. 
In my clinical study ULT had no effect on serum CCL2 levels but confirmed 
the positive associations between serum UA levels, blood monocyte 
percentages and CD11b expression. Soluble UA itself can act as a 
chemoattractant for eosinophils211. Therefore, it may be acting directly to 
recruit monocyte precursors from the bone marrow. However, this does not 
rule out a role for soluble UA in mediating CCL2 production. The degree of UA 
lowering may not have been sufficient to cause a decrease in serum CCL2, as 
patient serum UA levels did not reach the therapeutic target (<0.36mM). 
 
The human ULT study also showed that CD11b and ICAM1 expression on 
LPS-activated blood monocytes positively correlated with serum UA levels. In 
contrast, in vitro hyperuricaemia had no effect on monocyte adhesion 
molecule expression regardless of LPS stimulation, although ICAM1 was not 
measured in vitro. This could be an example of differences between in vitro 
and clinical hyperuricaemia where the in vitro UA incubation times may have 
been too short to result in any changes in adhesion molecule expression. For 
example, during ULT monocytes were exposed to lower serum UA levels for 
up to 28 days whereas with in vitro hyperuricaemia monocytes were only 
treated with soluble UA for a maximum of 18hr.  
 
Nevertheless, my research has identified a potential mechanism whereby 
increased serum UA levels contribute to monocyte recruitment into the 
circulation and movement between the circulation and the tissues through 
increased expression of the adhesion molecule CD11b. To complement this 
increased ICAM1 expression on tubular epithelial cells in the presence of 
hyperuricaemia has been shown to contribute to monocyte/macrophage renal 
infiltration147. Additionally, increased monocyte ICAM1 expression induced by 
hyperuricaemia may act to increase cell-cell binding between LPS-stimulated 
monocytes as observed in the homotypic aggregation studies in Chapter 3. 
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6.4 Murine hyperuricaemia and urate-lowering therapy 
6.4.1 Acute hyperuricaemia and ULT with allopurinol and rasburicase 
In vivo hyperuricaemia suppressed the systemic innate immune response to 
LPS and lowering serum UA in vivo produced the opposite effect. Allopurinol 
and rasburicase are both used clinically for the treatment of hyperuricaemia 
and both were equally effective at acutely lowering serum UA levels in C57 
mice.  
 
Clinically rasburicase reduces serum UA much faster than allopurinol54. 
Therefore, we could hypothesise that rasburicase would produce a more 
pronounced increase in pro-inflammatory cytokines in my model of systemic 
inflammation. However, rasburicase was less effective at increasing LPS-
induced systemic inflammation, as measured by serum cytokine production, 
than allopurinol.  
Additionally, the signalling response of splenic monocytes to LPS stimulation 
differed in allopurinol and rasburicase treated mice. Allopurinol predominantly 
affected the NFκB pathway by reducing IκBα and increasing NFκB p65 
subunit nuclear translocation, while rasburicase treatment raised ASC and 
increased NFκB.  
These differences in cytokine production and signalling may be a result of 
differences in the mechanism of action of allopurinol and rasburicase.  
Allopurinol is a small molecule inhibitor that reduces serum UA by inhibiting 
intracellular UA production by XOR58. Rasburicase, a recombinant enzyme, is 
much larger and less likely to enter cells without being actively taken up and is 
therefore more likely to function as an extracellular enzyme within the 
circulation. Even though both treatments resulted in equivalent serum UA 
lowering, allopurinol may be more effective at altering immune cell function by 
directly reducing intracellular UA concentrations.  
Additionally, rasburicase and allopurinol could have differential effects on 
ROS dependent inflammatory signalling212 as oxidation of UA by uricase213 
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and inhibition of XOR with allopurinol214 can increase and decrease ROS 
production respectively. 
 
6.4.2 The PLT2 mouse strain as a model for chronic hyperuricaemia 
Human hyperuricaemia is often a chronic condition and it is important to 
model a disease as closely as possible to avoid introducing experimental 
artefacts. To this end I investigated the suitability of the PLT2 strain as a 
model of chronic hyperuricaemia and ULT in the context of LPS-induced 
inflammation. 
  
When comparing PLT2 mice to C57 mice there was a 2-fold increase in 
serum UA and LPS challenge increased pro-inflammatory serum cytokines 
and IL-10. This increase in pro-inflammatory serum cytokines in the PLT2 
strain was not consistent with the effect of acute hyperuricaemia in C57 mice 
and did not correspond with human monocyte responses to hyperuricaemia 
and LPS. There were no changes in splenic monocyte inflammatory signalling 
pathways between PLT2 and C57 mice. The lack of changes in splenic 
monocyte signalling between the two mouse strains may be a result of life-
long exposure in the PLT2 strain to higher serum UA levels, causing the PLT2 
mouse immune system to adjust to the chronic UA exposure.  
Even though the PLT2 strain was hyperuricaemic in comparison to C57 mice, 
results from the PLT2 strain were not comparable to acute hyperuricaemia in 
C57 mice. Therefore, further research will be required to ascertain whether 
the PLT2 strain is a useful tool to model inflammation in the context of chronic 
hyperuricaemia. An important consideration will be the potentially confounding 
effects of other disturbances in immunological homeostasis caused by 
knockout of HIU hydrolase, as the PLT2 strain also has increased platelets 
compared to C57 mice and is predisposed to the development of liver 
cancer90. 
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The mechanism through which knockout of HIU hydrolase increases serum 
UA in the PLT2 strain is unknown but could involve product inhibition of 
uricase by HIU combined with naturally low renal UA excretion. I found that a 
single dose of allopurinol within a 3hr timeframe had no effect on serum UA 
levels or cytokine and signalling responses to LPS in the PLT2 strain. 
Although UA production would have been blocked by allopurinol treatment the 
reduced capacity for UA metabolism in the PLT2 strain could potentially 
explain why there was no effect of allopurinol at this time point.  
Subsequent research in the Harper group has found that 7 days of allopurinol 
treatment, administered via the drinking water, can significantly reduce serum 
UA in the PLT2 strain (unpublished data). This indicates that allopurinol can 
lower serum UA in the PLT2 strain but that more time is required to excrete or 
metabolise the excess UA.  
On the other hand, acute rasburicase treatment did reduce serum UA in PLT2 
mice as, unlike allopurinol, addition of exogenous uricase increases UA 
metabolism. Rasburicase also increased inflammatory monocyte signalling. 
However, the degree of UA lowering in my experiments and the short time 
frame may not have been sufficient to fully reverse the suppressive effects of 
chronic hyperuricaemia and increase pro-inflammatory serum cytokines in 
response to LPS.  
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6.5 Modulating soluble UA as a method of controlling 
inflammation and disease 
In vitro, in vivo and clinical hyperuricaemia suppressed monocyte pro-
inflammatory cytokine production in response to LPS and, importantly, 
increased IL-10 production. I also showed clinically that monocyte number 
and adhesion molecule expression increase with increasing hyperuricaemia. 
Together these results demonstrate a suppressive effect of soluble UA on 
systemic and monocyte cytokine production and an augmentation of 
monocyte migratory ability. The potential consequences of these findings in 
the context of hyperuricaemia and different disease processes are discussed 
here. 
 
6.5.1 Hyperuricaemia and sepsis 
I have shown that in vivo pharmacomanipulation of serum UA has the 
potential to influence inflammation during low dose LPS but whether 
hyperuricaemia is protective or exacerbates sepsis is still not clear. In human 
studies there are reports of gross immunosuppression in tissues from septic 
patients analysed post-mortem215,216 and  serum UA has been shown to 
increase in patients with sepsis, which correlates with the severity of 
disease217. In mouse models increased proinflammatory cytokines and 
decreased IL-10 levels are associated with increased mortality during 
peritonitis218 and in a model of neutropenia that causes hyperuricaemia 
lowering serum UA with allopurinol was shown to increase survival in LPS 
challenged mice219.   
 
Taken together, the current literature provides evidence supporting a role for 
hyperuricaemia in exacerbating sepsis by contributing to immunosuppression. 
Consequently, ULT to reduce or prevent immunosuppression during sepsis 
could potentially aid in the inflammatory cytokine response and clearance or 
killing of bacteria. 
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6.5.2 Hyperuricaemia and metabolic syndrome 
The physiological functions of hyperuricaemia have been widely investigated 
but there is still debate over the contribution of hyperuricaemia to metabolic 
dysfunction2. My findings may shed some light on how hyperuricaemia 
moderates or contributes to these diseases from an immunological 
perspective.  
 
The formation and exacerbation of cardiovascular disease is a process 
involving monocyte recruitment to damaged vascular endothelium, 
differentiation into macrophages and phagocytosis of cholesterol crystals127. 
Whether this process results in enlargement or regression of the 
atherosclerotic plaque is dependent on a multitude of factors including the 
phenotype of the resident macrophage220   
Obesity is characterised by chronic low-grade inflammation, endocrine 
imbalance and increased adipose tissue macrophages. Hyperuricaemia has 
been shown to contribute to monocyte recruitment to adipose tissue and 
insulin resistance72,221.  
Results from the ULT study indicate that there are increased monocyte 
numbers in the circulation during hyperuricaemia with a greater potential for 
adhesion and migration through increased expression of adhesion molecules. 
This indicates that hyperuricaemia may directly contribute to the development 
and severity of cardiovascular disease and obesity through increased 
monocyte recruitment.  
However, the development of hyperuricaemia during cardiovascular disease 
or obesity could be a regulatory mechanism designed to counteract the 
chronic inflammation. Hyperuricaemia could enhance recruitment of 
suppressive monocytes into atherosclerotic plaques or adipose tissue in an 
attempt to resolve the chronic inflammation. 
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6.5.3 Soluble versus crystalline uric acid 
The results of this thesis demonstrate that soluble UA has a suppressive 
effect on monocyte inflammatory potential. On the other side of the spectrum 
is the well-established pro-inflammatory nature of crystalline UA (MSU). MSU 
is a powerful immune adjuvant that triggers pro-inflammatory cytokine 
production, NLRP3 inflammasome activation and dendritic cell maturation to 
promote both innate and adaptive immune responses77,114,222,223.  
 
By integrating these two opposing functions of soluble and crystalline UA I 
have developed a theory that positions UA as a key regulator of local 
inflammation that can direct the switch from innate to adaptive immunity 
(figure 6.2). 
 
Local tissue environments can become hyperuricaemic as a result of cell 
death induced by injury or infection, as soluble UA is rapidly released from 
dying cells107. My in vitro, in vivo and clinical study results all indicate that 
monocytes entering a tissue environment with high levels of soluble UA would 
be less inflammatory upon stimulation with damage associated or pathogen 
associated molecular patterns (DAMPs or PAMPs) present due to the injury or 
infection.  
This local rise in soluble UA could be important for containing the immune 
response during low-level damage or a minor infection (figure 6.2). Increased 
soluble UA levels may also aid in the migration of monocytes towards the site 
of inflammation by increasing adhesion molecule expression on both 
monocytes and cells in the affected tissue147.  
However, if the damage or infection were severe enough the tissue would 
become supersaturated with soluble UA to the point where UA crystallisation 
occurs in order to activate a potent inflammatory response (figure 6.2).  
In this way soluble UA could act as an inhibitory danger signal that 
discourages an overactive innate immune response or unnecessary adaptive 
immune response to a minor insult and limits the chances of a break in 
peripheral tolerance. The crystal switch to MSU would occur when the innate 
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response is unable to contain the damage and would facilitate the 
development of potent innate and adaptive immune responses (figure 6.2). 
 
 
 
 
Figure 6.2 Proposed model of soluble UA controlling low-level inflammation 
and the switch to crystalline UA (MSU) activating innate and adaptive 
immunity during severe inflammation. 
The font size of cytokines reflects their relative concentration. 
Circulation
Tissue
Soluble
Uric Acid
Low level in!ammation
Monocytes
Neutrophils
IL-10
TNFα
IL-6
IL-12p40
IL-1β
Crystalline
Uric Acid (MSU)
Neutrophils
Monocytes
Control by Innate Immunity Activation of Adaptive Immunity
Bacteria/Antigen
Di$erentiation
Tissue damage or infection
Di$erentiation
Bacteria/Antigen
Circulation
Tissue
IL-10
TNFα
IL-6
IL-12p40
IL-1β
Resident 
Macrophages
Resident DC
In!ammatory 
Macrophages
Activated DC
Chapter 6: Discussion and Future Directions 
 
138 
6.6 Future directions 
6.6.1 Immune cell signalling 
I have shown that soluble UA modulates monocyte signalling during 
inflammation. Therefore, the next question is how does UA specifically 
interact with these signalling molecules. It is clear that soluble UA affects 
several inflammatory signalling pathways; namely the MAP kinase, NFκB and 
the NLRP3 inflammasome; but whether UA has a single mechanism of action 
that is broad reaching or alters the different pathways through individual 
interactions is not known.  
 
There are indications that soluble UA may be involved in protein ubiquitination 
or deSUMOylation, although there is no direct evidence that soluble UA can 
enhance ASC ubiquitination and there are no reports yet of ASC SUMOylation. 
These modifications are functionally diverse and could potentially explain the 
broad impact of soluble UA across the different inflammatory signalling 
pathways. Co-immunoprecipitation experiments, using protein isolated from 
monocytes treated with soluble UA, could be used to extract ASC. Western 
blotting could then be used to determine whether soluble UA alters 
ubiquitination or SUMOylation of ASC. Other potential target proteins such as 
NLRP3 and DUSP10 could also be investigated for ubiquitination and 
SUMOylation levels in the presence of hyperuricaemia. 
 
The majority of this work involved stimulation of the monocyte TLR4 pathway 
with LPS. This has dictated, to some extent, the signalling pathways I have 
investigated. However, these signalling pathways are not unique to 
monocytes or LPS stimulation. Additionally, inflammasome independent 
functions of ASC are not unique to monocytes, having been demonstrated in 
dendritic cells and T-cells177,224. The effect of soluble UA on cytokine 
production and antigen presentation in myeloid cells, and the proliferation and 
antibody production of T and B-cells would be an excellent starting point to 
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broaden this line of research and determine the extent of soluble UA’s role in 
immune cell modulation. 
 
6.6.2 Adhesion and migration 
The clinical study confirmed that hyperuricaemia is augmenting monocyte 
recruitment into the circulation and also increasing adhesion molecule 
expression on these monocytes.  
I did not measure monocyte ICAM1 expression in vitro but the clinical study 
suggests that the increased monocyte homotypic aggregation I observed with 
in vitro hyperuricaemia and LPS stimulation could be a result of increased 
ICAM1 expression through its interaction with CD11b192. This could be 
investigated by measuring ICAM1 expression on monocytes following in vitro 
hyperuricaemia and LPS stimulation in combination with blocking antibodies 
for ICAM1 and CD11b. This could be followed up with antibody labelling of 
CD11b and ICAM1 and fluorescent microscopy to determine whether these 
molecules colocalise at the point of monocyte-monocyte interaction. 
The next experimental step could be in vivo analysis of monocyte migration 
into tissues and the contribution of adhesion molecules to this process. The 
migratory potential could be investigated by measuring monocyte infiltration in 
mouse models of local inflammation, such as peritonitis or atherosclerosis, 
combined with hyperuricaemia or ULT.  
Measuring rolling and tethering of monocytes under laminar flow and in the 
presence of hyperuricaemia could be used to determine whether the 
increased adhesion molecule expression translates to a quantifiable gain of 
adhesive function. These experiments could be combined with blocking 
different adhesion molecules to determine the extent of the contribution of 
each. 
In this way monocyte recruitment into the tissues could be measured 
alongside their ability to adhere to and cross the vascular endothelium in 
response to different inflammatory stimuli and changes to circulating soluble 
UA levels.   
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6.6.3 Murine hyperuricaemia and urate-lowering therapy 
Pharmacologically induced acute hyperuricaemia was sufficient to induce a 
suppressive inflammatory response to systemic LPS challenge. However, 
C57 mice with acute hyperuricaemia responded differently than PLT2 mice 
with chronic hyperuricaemia to LPS challenge. This may be a reflection of 
different effects of acute vs. chronic hyperuricaemia. To study this further 
pharmacological induction of chronic hyperuricaemia in C57 mice could be 
compared to genetic hyperuricaemia in the PLT2 strain to ascertain the 
suitability of the PLT2 strain as a model of chronic hyperuricaemia. As human 
hyperuricaemia is predominantly chronic it would be important to validate a 
chronic model of hyperuricaemia for use in further studies. 
Well-defined and validated chronic models of hyperuricaemia would then 
allow for the development of chronic ULT models combined with immune 
challenge. C57 mice with acute ULT responded to LPS with a reversal of the 
inflammatory phenotype produced by acute hyperuricaemia and LPS. 
However, monocyte immune suppression caused by chronic hyperuricaemia 
may be more profound than those caused by acute hyperuricaemia and could 
require long-term ULT to achieve a phenotypic reversal.  
The PLT2 strain was refractory to acute allopurinol treatment but preliminary 
results showed that 1 week of allopurinol treatment via the drinking water 
lowered PLT2 mouse serum UA. The next step would be to investigate the 
effect of chronic ULT on inflammation in the PLT2 strain. 
The differential effects of rasburicase and allopurinol on monocyte signalling 
molecules provides a rationale for combination therapy as there may be an 
additive or even synergistic effect on immune cell responses to inflammation 
when both therapies are used together. For example, the rapid urate lowering 
effects of an initial bolus rasburicase dose could be followed up with long-term 
allopurinol treatment to maintain urate lowering and ensure intracellular UA is 
lowered efficiently. If reducing serum UA also increases the inflammatory 
potential of other immune cells then different ULT dosing schedules could be 
investigated to optimise the augmentation of inflammatory responses in 
different cell types. 
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6.6.4 Human urate-lowering therapy studies  
The human ULT study was not initially designed to determine the effects of 
serum UA levels on immune cell function. This meant that lowering UA was 
not the main goal of the study and the final measurement (day 28) was taken 
before the patients reached target serum UA levels (<0.36mM). It would be 
ideal to resample the 15 patients from the ULT study once they have reached 
0.36mM to compare the suppressive effect of hyperuricaemia to 
normouricaemia. This could be combined with the sampling and analysis of 
15 healthy, age and gender matched controls to see whether the suppressive 
effects of hyperuricaemia on monocyte function are truly plastic. In this case 
we could hypothesise that monocyte immune function in patients who have 
reached target UA levels would return to normal and be equivalent to that of 
monocytes from healthy controls. 
 
Currently ULT is only prescribed for hyperuricaemia associated with gout or 
tumour lysis syndrome. My ULT study showed that lowering serum UA levels 
increased the inflammatory potential of blood monocytes but decreased blood 
monocyte numbers and migratory potential. These results provide a rationale 
for the treatment of hyperuricaemia associated with diseases where monocyte 
infiltration is a known mediator of the pathophysiology, such as cardiovascular 
disease and obesity72,220. This could begin with an allopurinol safety and 
efficacy trial enrolling normo- and hyperuricaemic participants who are 
otherwise healthy or suffer from different metabolic syndrome related 
diseases. It could be expanded to include other methods of ULT and it could 
also look at other circulating immune cells in the context of their inflammatory 
potential to cell specific stimuli. It would be important to include 
measurements of patient disease burden and recovery to establish whether 
these parameters are linked to changes in serum UA and immune cell 
function. Finally, extreme care should be taken to carefully define and 
evaluate safety parameters and primary outcomes as my results also indicate 
that ULT could potentially exacerbate inflammation by removing the 
suppressive effects of hyperuricaemia. 
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7 Appendices 
 
7.1 NFκB signalling in human monocytes following in vitro UA 
treatment 
 
 
Figure 7.1 NFκB p65 nuclear translocation is inhibited and p50 in enhanced 
by soluble UA.  
Western blot of nuclear NFκB p65 and p50 subunits from human blood monocytes 
pre-treated with or without UA (0.6mM) for 2hr and 15, 30 or 60min with LPS 
(100ng/ml). Tata binding protein (TBP) was used as a loading control. Monocyte 
western blots were analysed with ImageJ software to determine band density and 
normalised to loading controls (TBP) and unstimulated control (lane1). Results 
represent three independent experiments from individual volunteers. 
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7.2 MAP kinase signalling in human monocytes following in vitro 
UA treatment 
 
 
Figure 7.2 p38 and ERK1/2 MAP kinases are more rapidly dephosphorylated 
in UA treated monocytes.  
Western blot of cytosolic MAP kinase phosphorylation from human blood monocytes 
pre-treated with or without UA (0.6mM) for 2hr and 20 or 60min with LPS (100ng/ml). 
β-actin was used as a loading control.Monocyte western blots were analysed with 
ImageJ software to determine band density and normalised to loading controls (β-
actin) and unstimulated control (lane1). Results represent three independent 
experiments from individual volunteers. 
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7.3 Densitometric analysis of western blot data from figure 4.5 
and 4.6 
 
Figure 7.3 Densitometric analysis of western blot data from figure 4.5 and 
4.6. 
A-E and H-L: Cytosolic and F-G: nuclear protein from purified splenic monocytes 
isolated from C57 mice (n=5) pre-treated with or without oxonic acid (OA 300mg/kg, 
30min) and UA (12ug/kg, 1hr), then administered LPS i.v. (40ng/kg, 1hr). Protein was 
analysed by western blotting. Results are representative of two independent 
experiments. Monocyte western blots were analysed with ImageJ software to 
determine band density and normalised to loading controls (β-actin) and 
unstimulated control (lane1).  
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7.4 Densitometric analysis of western blot data from figure 4.8 
 
Figure 7.4 Densitometric analysis of western blot data from figure 4.8. 
A-E: Cytosolic and F-G: nuclear protein from purified splenic monocytes isolated 
from C57 mice (n=5) pre-treated with or without allopurinol (30mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Monocyte western blots 
were analysed with ImageJ software to determine band density and normalised to 
loading controls (β-actin) and unstimulated control (lane1). 
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7.5 Densitometric analysis of western blot data from figure 4.10 
 
Figure 7.5 Densitometric analysis of western blot data from figure 4.10. 
A-E: Cytosolic and F-G: nuclear protein from purified splenic monocytes isolated 
from C57 mice (n=5) pre-treated with or without rasburicase (0.8mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Monocyte western blots 
were analysed with ImageJ software to determine band density and normalised to 
loading controls (β-actin) and unstimulated control (lane1). 
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7.6 Densitometric analysis of western blot data from figure 4.11 
 
Figure 7.6 Densitometric analysis of western blot data from figure 4.11. 
Cytosolic protein from purified splenic monocytes isolated from C57 mice (n=5) pre-
treated with or without allopurinol (30mg/kg, 3hr) or rasburicase (0.8mg/kg, 3hr) then 
administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Monocyte western blots 
were analysed with ImageJ software to determine band density and normalised to 
loading controls (β-actin) and unstimulated control (lane1). 
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7.7 Densitometric analysis of western blot data from figure 4.14 
and 4.15 
 
Figure 7.7 Densitometric analysis of western blot data from figure 4.14 and 
4.15. 
A-E and H-L: Cytosolic and F-G: nuclear protein from purified splenic monocytes 
isolated from C57 and PLT2 mice (n=5) administered LPS i.v. (40ng/kg, 1hr). Protein 
was analysed by western blotting. Strain: C = C57 and P = PLT2. Results are 
representative of two independent experiments. Monocyte western blots were 
analysed with ImageJ software to determine band density and normalised to loading 
controls (β-actin) and unstimulated control (lane1). 
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7.8 Densitometric analysis of western blot data from figure 4.17 
and 4.18 
 
Figure 7.8 Densitometric analysis of western blot data from figure 4.17 and 
4.18. 
A-E and H-L: Cytosolic and F-G: nuclear protein from purified splenic monocytes 
isolated from PLT2 mice (n=5) pre-treated with or without allopurinol (30mg/kg, 3hr) 
then administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western blotting. 
Results are representative of two independent experiments. Monocyte western blots 
were analysed with ImageJ software to determine band density and normalised to 
loading controls (β-actin) and unstimulated control (lane1). 
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7.9 Densitometric analysis of western blot data from figure 4.20 
and 4.21 
 
Figure 7.9 Densitometric analysis of western blot data from figure 4.20 and 
4.21. 
A-E and H-L: Cytosolic and F-G: nuclear protein from purified splenic monocytes 
isolated from PLT2 mice (n=5) pre-treated with or without rasburicase (0.8mg/kg, 
3hr) then administered LPS i.v. (40ng/kg, 1hr). Protein was analysed by western 
blotting. Results are representative of two independent experiments. Monocyte 
western blots were analysed with ImageJ software to determine band density and 
normalised to loading controls (β-actin) and unstimulated control (lane1). 
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7.10 Serum cytokines and chemokines during ULT 
 
Figure 7.10 ULT does not alter human serum cytokine or chemokine levels.  
Cytokines and chemokines in human serum from day 0, day 1 and day 28 of ULT 
were analysed by multiplex bead array. A: IL-10, B: IL12p40, C: IL-6, D: TNFα, E: IL-
1β, F: IL-1Ra, G: IL-8, H: CCL4, I: CCL5, J: CCL7. 
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7.11 Serum cytokines and chemokines versus serum UA levels 
 
Figure 7.11 Serum IL-10 and IL-8 levels negatively correlate with serum UA.  
Cytokines and chemokines in human serum from day 0, day 1 and day 28 of ULT 
were analysed by multiplex bead array. A: IL-10, B: IL12p40, C: IL-6, D: TNFα, E: IL-
1β, F: IL-1Ra, G: IL-8, H: CCL4, I: CCL5, J: CCL7. *p<0.05, Pearson’s correlation 
coefficient.  
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7.12 Clinical western blots of LPS treated monocytes 
 
Figure 7.12 Western blots of LPS treated monocyte cytosolic protein from 
patients undergoing ULT.  
Cytosolic protein was isolated from blood monocytes purified from patients before (0) 
and after 1 and 28 days of ULT. Monocytes were unstimulated (n=8) or stimulated for 
1hr with A: LPS (100ng/ml n=4) or B: MSU (0.5mg/ml n=4). Protein extracts were 
analysed by western blotting. A, B, C and D correspond with patient experimental 
numbers 7, 10, 12 and 14 respectively. 
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7.13 Clinical western blots of MSU treated monocytes 
 
Figure 7.13 Western blots of MSU treated monocyte cytosolic protein from 
patients undergoing ULT. Cytosolic protein was isolated from blood monocytes 
purified from patients before (0) and after 1 and 28 days of ULT. Monocytes were 
unstimulated (n=8) or stimulated for 1hr with A: LPS (100ng/ml n=4) or B: MSU 
(0.5mg/ml n=4). Protein extracts were analysed by western blotting. A, B, C and D 
correspond with patient experimental numbers 9, 11, 13 and 15 respectively. 
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